EurekaMag PDF full texts Chapter 48,834

Stuettgen, G. 1961: Drug allergies from the viewpoint of the dermatologist. Allergie- und Asthmaforschung 4: 27-33

Sachs, B.; Merk, H.F. 2005: Drug allergies. Clinical aspects, pathophysiology and treatment of cutaneous manifestations. Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 56(1): 8-15

McCOMBS, R.P. 1951: Drug allergies; case reports of unusual sequelae in three patients. Bulletin. new England Medical Center 13(1): 39-44

Honsinger, R.W. 2004: Drug allergy. Annals of Allergy Asthma and Immunology: Official Publication of the American College of Allergy Asthma and Immunology 93(2): 111

Henderson-Begg, A. 1958: Drug allergy and contact dermatitis. East African Medical Journal 35(11): 621-624

Gerasimova, M.M. 2005: Drug allergy and nervous system disorders. Likars'ka Sprava 2005(1-2): 48-51

Schwaner, H.L. 1953: Drug allergy as cause of sudden death. Deutsche Zeitschrift für die Gesamte Gerichtliche Medizin 42(4-5): 443-444

Mora Nieto, A.; Segura Méndez, N.H.; Almeida Arvizu, V.; Díaz Torres, M.T.; Martínez Pérez, T. 2006: Drug allergy assessed by modified Shelley's test. a case series. Revista Alergia Mexico 53(3): 89-93

Kaiser, W.; Morgenstern, A. 1956: Drug allergy following gold medication. Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 11(18): 848-850

Thong, B.Yu-Hor.; Leong, K-Pang.; Tang, C-Ying.; Chng, H-Hee. 2003: Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Annals of Allergy Asthma and Immunology: Official Publication of the American College of Allergy Asthma and Immunology 90(3): 342-347

Kost, E.A. 1952: Drug allergy in agranulocytosis, hemorrhagic aleukia, and panmyelophthisis. Klinicheskaia Meditsina 30(12): 31-36

Erdmann, G. 1961: Drug allergy in childhood. Allergie- und Asthmaforschung 4: 14-27

Rabinowitz, H.; Halpern, S.R. 1960: Drug allergy in pediatric practice. Journal of Pediatrics 56: 75-90

Zhu, Z.-h.; Yu, G.-y.; Zhou, L.-h.; Xu, L.; Zhang, S.-y. 2005: Drug allergy induced salivary and lacrimal diseases: clinical analysis of 25 cases. Zhonghua Yi Xue Za Zhi 85(6): 422-423

Nieminen, E.; Hyry, H.; Lauerma, A.; Granlund, H.åk.; Haahtela, T. 2004: Drug allergy syndromes in adults, what is the right time to test for hypersensitivity?. Duodecim; Laaketieteellinen Aikakauskirja 120(15): 1885-1890

Kawakami, T. 1962: Drug allergy, with special reference to countermeasures and management of drug shock. Therapy 44: 543-554

Feinberg, S.M. 1952: Drug allergy--some clinical and immunological aspects. Annals of Allergy 10(3): 260-269

Solensky, R. 2004: Drug allergy: desensitization and treatment of reactions to antibiotics and aspirin. Clinical Allergy and Immunology 18: 585-606

Jenkins, C.M. 1953: Drug allergy: newer forms of treatment. Journal of the National Medical Association 45(4): 241-247

Fischer, H. 1951: Drug allergy; facts and problems. Schweizerische Medizinische Wochenschrift 81(38): 890-900

Harten, P. 2003: Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE). Medizinische Klinik 98(6): 344; Author Reply 344-5

Huong, P.V. 1986: Drug analysis by Raman and micro-Raman spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 4(6): 811-823

Johnson, C.A. 1986: Drug analysis--why?. Journal of Pharmaceutical and Biomedical Analysis 4(6): 689-696

Basu, D.; Singh, J. 2005: Drug and alcohol abuse: general physician's perspective. Journal of the Indian Medical Association 103(2): 88; 90 92 Passim

Novak, H.; Petch, I. 1994: Drug and alcohol education in New South Wales: what do nurses want to learn?. Drug and Alcohol Review 13(2): 185-193

Anderson, P. 2006: Drug and alcohol policy at the global level. Drug and Alcohol Review 25(6): 485-487

Gunter, T.D.; Black, D.W.; Zwick, J.; Arndt, S. 2004: Drug and alcohol treatment services effective for methamphetamine abuse. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists 16(4): 195-200

Deutch, S.ør.R.; Christian, C.; Hoyer, S.; Christensen, E.F.; Dragsholt, C.; Hansen, A.C.; Kristensen, I.B.; Hougaard, K. 2004: Drug and alcohol use among patients admitted to a Danish trauma centre: a prospective study from a regional trauma centre in Scandinavia. European Journal of Emergency Medicine: Official Journal of the European Society for Emergency Medicine 11(6): 318-322

Armstrong, E.M. 2005: Drug and alcohol use during pregnancy: we need to protect, not punish, women. Women's Health Issues: Official Publication of the Jacobs Institute of Women's Health 15(2): 45-47

Milling, T.John. 2005: Drug and alcohol use in emergency medicine residency: an impaired resident's perspective. Annals of emergency medicine 46(2): 148-151

Ross, A. 2003: Drug and alcohol work in child and adolescent mental health. Nursing Times 99(29): 26-27

Christian, J.R. 1962: Drug and chemical poisonings and their management. Medical Science 12: 37-46

Garston, L.E. 1953: Drug and chemical sensitization. Connecticut State Medical Journal 17(1): 18-24

Probst, W. 2005: Drug and digestive probes. Aspects of pharmaceutical care. Medizinische Monatsschrift für Pharmazeuten 28(11): 376-388; Quiz: 389-390

Davey, J.D.; Davey, T.; Obst, P.L. 2005: Drug and drink driving by university students: an exploration of the influence of attitudes. Traffic Injury Prevention 6(1): 44-52

Gregory, C. 2006: Drug and enteral feed interactions. Journal of Human Nutrition and Dietetics: the Official Journal of the British Dietetic Association 19(3): 237-239

Bae, Y.; Kataoka, K. 2006: Drug and gene delivery with nanotechnology. Seikagaku. Journal of Japanese Biochemical Society 78(9): 882-887

Goerisch, V. 1959: Drug and laboratory devices from the Deutsche Demokratische Republik from the Leipzig Spring Fair of 1959. Pharmazeutische Praxis 10: 153-156

Meissner, B.; Dickson, M.; Shinogle, J.; Reeder, C.E.; Belazi, D.; Senevirante, V. 2006: Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. Journal of Managed Care Pharmacy: Jmcp 12(4): 331-340

Rüsing, D.; Bauer, K.; Verspohl, E.J. 2004: Drug and medicinal products for the consumer. a critical evaluation. Medizinische Monatsschrift für Pharmazeuten 27(3): 84-91

Rashkis, H.A.; Smarr, E.R. 1957: Drug and milieu effects with chronic schizophrenics. A.M.A. Archives of Neurology and Psychiatry 78(1): 89-94

Depagne, C.; Louerat, C.; Nesme, P. 2003: Herpes simplex and Geotrichum candidum pneumonia in a patient with moderate renal failure. Revue de Pneumologie Clinique 59(5 Part 1): 297-300

Le Houezec, J.; Säwe, U. 2003: Smoking reduction and temporary abstinence: new approaches for smoking cessation. Journal des Maladies Vasculaires 28(5): 293-300

Beyens, M.-N.ël.; Guy, C.; Ratrema, M.; Ollagnier, M. 2003: Prescription of drugs to pregnant women in France: the HIMAGE study. Therapie 58(6): 505-511

Kollotzek, H. 1963: Drug and placebo effect in disorders of the autonomic nervous system in a cross double-blind experiment. Die Medizinische Welt 14: 758-762

Liberman, R.Paul.; Glick, I.D. 2004: Drug and psychosocial curricula for psychiatry residents for treatment of schizophrenia: part I. Psychiatric Services 55(11): 1217-1219

Liberman, R.Paul. 2005: Drug and psychosocial curricula for psychiatry residents for treatment of schizophrenia: part II. Psychiatric Services 56(1): 28-30

Clatts, M.C.; Goldsamt, L.A.; Yi, H. 2005: Drug and sexual risk in four men who have sex with men populations: evidence for a sustained HIV epidemic in new York City. Journal of Urban Health: Bulletin of the new York Academy of Medicine 82(1 Suppl 1: I9-17

McCLUSKEY, C.M. 1959: Drug and solution control. Hospital Management 87(2): 105-107 Contd

McCLUSKEY, C.M. 1959: Drug and solution control. Ii. Hospital Management 87(3): 106 Passim

Schiffman, R.F. 2004: Drug and substance use in adolescents. Mcn. American Journal of Maternal Child Nursing 29(1): 21-27; Quiz: 28-29

Schild, H.O. 1957: Drug antagonism and pAx. Pharmacological Reviews 9(2): 242-246

Adriani, J.; Drake, P. 1961: Drug antagonists: their use in anesthesiology. Anesthesia and Analgesia 40: 591-597

Bertsche, T.; Bardenheuer, H.J. 2006: Drug application forms in chronic pain therapy. Therapeutische Umschau. Revue Therapeutique 63(6): 391-397

Pfaff, A. 2006: Drug application in patients with artificial nutritional support via tubes. Therapeutische Umschau. Revue Therapeutique 63(6): 423-432

Laustsen, G.; Wimett, L. 2004: Drug approval highlights for 2003. Nurse practitioner 29(2): 8

Eggertson, L. 2005: Drug approval system questioned in US and Canada. Cmaj: Canadian Medical Association Journal 172(3): 317-318

Laustsen, G.; Gilbert, M.; Wimett, L. 2007: Drug approvals. Nurse Practitioner 32(2): 43-51; Quiz 51-2

Preskorn, S.H. 2002: Drug approvals and withdrawals over the last 60 years. Journal of Psychiatric Practice 8(1): 41-50

Cuny, L. 1951: Drug assay committee. Gazette Medicale de France Spec. No.: 397-399

Ambrose, E.J.; Andrews, R.D.; Easty, D.M.; Field, E.O.; Wylie, J.A. 1962: Drug assays on cultures of human tumour biopsies. Lancet 1(7219): 24-25

Hanson, K. 2003: Drug assistance from drug makers. State Legislatures 29(6): 22-24

Wiesendanger, B. 1960: Drug assortment for the Defense Corps. Vierteljahrsschrift für Schweizerische Sanitatsoffiziere. Journal Trimestriel des Officiers Suisses du Service de Sante. Rivista Trimestrale Degli Ufficiali Sanitari Svizzeri 37: 66-70

Jansson, B. 1961: Drug automatism as a cause of pseudo suicide. Postgraduate Medicine 30: A34-A40

Jansson, B. 1961: Drug automatism--a source of error in suicide statistics. Nordisk Medicin 66: 1529-1534

Anonymous 2003: Drug available to treat enlarged prostate. Mayo Clinic Health Letter 21(7): 4

Anonymous 2005: Drug being developed to treat cervical dysplasia. Aids Patient Care and Stds 19(5): 351-352

Cline, R.R.; Gupta, K. 2006: Drug benefit decisions among older adults: a policy-capturing analysis. Medical Decision Making: An International Journal of the Society for Medical Decision Making 26(3): 273-281

Rodgers, J. 2005: Drug bills and medicare part D. Health Affairs 24(6): 1690; Author Reply 1690

Kuroda, Y.; Shibukawa, A.; Nakagawa, T. 2003: Drug binding analysis of human alpha 1-acid glycoprotein using capillary electrophoresis. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 123(9): 781-788

Karwatsky, J.M.; Georges, E. 2004: Drug binding domains of MRP1 (ABCC1) as revealed by photoaffinity labeling. Current Medicinal Chemistry. Anti-Cancer Agents 4(1): 19-30

Ilag, L.L.; Ubarretxena-Belandia, I.; Tate, C.G.; Robinson, C.V. 2004: Drug binding revealed by tandem mass spectrometry of a protein-micelle complex. Journal of the American Chemical Society 126(44): 14362-14363

Tillement, J-Paul.; Duché, J-Claude.; Barré, Jérôme. 2006: Drug binding to blood proteins: characteristics, roles and pathophysiological changes. Bulletin del'Academie Nationale de Medecine 190(4-5): 935

Zhou, S.; Chan, E.; Duan, W.; Huang, M.; Chen, Y.-Z. 2005: Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metabolism Reviews 37(1): 41-213

Cabezón Ruiz, S.; Morán Risco, J.E.; Pedrote Martínez, A.; Errazquin Sáenz de Tejada, F.; Cayuela, A.; Barón-Esquivias, G. 2003: Drug bradyarrhythmias as a cause of hospital admission. Study of 83 cases. Medicina Clinica 120(15): 574-575

Olsson, S.; Pal, S. 2006: Drug bulletins: independent information for global use. Lancet 368(9539): 903-904

Leslie, M. 2005: Drug bust. Science of Aging Knowledge Environment: Sage Ke 2005(44): Nf84

Tarnow, K.G.; Werst, C.L. 2000: Drug calculations examinations: do calculators make a difference?. Nurse Educator 25(5): 213-215

Pentin, J.; Smith, J. 2006: Drug calculations: are they safer with or without a calculator?. British Journal of Nursing 15(14): 778-781

Jongsma, M.W. 1960: Drug card for emergencies. Het Ziekenhuiswezen 33: 224-225

Gundling, R.L. 2003: Drug card setback highlights need for cost relief. Healthcare financial management: journal of the Healthcare Financial Management Association 57(4): 50-54

Senter, P.D.; Kopecek, J. 2004: Drug carriers in medicine and biology. Molecular Pharmaceutics 1(6): 395-398

Viskin, S. 2005: Drug challenge with epinephrine or isoproterenol for diagnosing a long QT syndrome: should we try this at home?. Journal of Cardiovascular Electrophysiology 16(3): 285-287

Sister Mary Daniel 1953: Drug charges; a small hospital problem. Hospital Management 76: 74

Burton, B. 2005: Drug chiefs ponder how to improve industry's reputation. Bmj 330(7502): 1229

Tepe, G.; Schmehl, J.; Claussen, C.D.; Ernemann, U.; Pereira, P.; Duda, S.H. 2005: Drug coated stents for carotid intervention. Journal of Cardiovascular Surgery 46(3): 249-259

Anonymous 2004: Drug combination can extend life for men with prostate cancer. Fda Consumer 38(4): 3

Anonymous 2006: Drug combination helps in goiter caused by iodine deficiency. MMW Fortschritte der Medizin 148(14): 63

Cimini, P.P. 1960: Drug combination in the treatment of depressive states. El Dia Medico 32: 1519-1521

Audran, M. 2006: Drug combination strategies for osteoporosis. Joint Bone Spine 73(4): 374-378

Anonymous 2004: Drug combination treats HIV and HCV. Aids Patient Care and Stds 18(4): 251

Snyder, F.A. 2005: Drug combinations and all cause mortality in heart disease: dosages and types of ACE inhibitors need to be known. Bmj 331(7509): 159; Author Reply 160

Bjorck, S. 2005: Drug combinations and all cause mortality in heart disease: no new insights were gained. Bmj 331(7509): 159; Author Reply 160

Vos, E. 2005: Drug combinations and all cause mortality in heart disease: use of statins is not supported by study. Bmj 331(7509): 159; Author Reply 160

Danchin, N. 2005: Drug combinations and cardiovascular prevention. Annales de Cardiologie et d'Angeiologie 54 Suppl. 1: S1

Slim, K. 2005: Abecedary of the "Annales". Part 6. Annales de Chirurgie 130(8): 498-500

Stahl, S.M. 2004: Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence?. Journal of Clinical Psychiatry 65(10): 1298-1299

Mondimore, F.M.; Fuller, G.A.; DePaulo, J.R. 2003: Drug combinations for mania. Journal of Clinical Psychiatry 64(Suppl 5): 25-31

Ranjan, S.; Chandra, P.S. 2005: Drug combinations for rapid tranquillisation. British journal of psychiatry: the journal of mental science 187: 192-3; author reply 193

Puig, M. 2006: Drug combinations in pain management. Journal of Pain and Palliative Care PharmacoTherapy 20(4): 51-53

Cernich, I.R.; Deluca, A.A.; Agnese, C.A.; Kroll Bieber, J.P. 1963: Drug combinations in rheumatology. El Dia Medico 35: 833

Felletti, V. 1961: Drug combinations in the therapy of pharyngeal inflammations with special reference to a new CAF-bismuth-sulfonamide preparation. Annali di Laringologia Otologia Rinologia Faringologia 60: 929-935

Robecchi, A. 1958: Drug combinations in the treatment of chronic evolutive rheumatism. Acta Medica Scandinavica. Supplementum 341: 199-203

Knox, R. 1956: Drug combinations in treatment of bacterial infections. Proceedings of the Royal Society of Medicine 49(11): 879-880

Xavier, H.T. 2005: Drug combinations: statins and fibrates. Arquivos Brasileiros de Cardiologia 85(Suppl 5): 34-35

Borges, J.L. 2005: Drug combinations: statins and niacin. Arquivos Brasileiros de Cardiologia 85(Suppl 5): 36-41

Anonymous 2004: Drug combo stalls BPH progression. Health News 10(2): 9

Carlsson, T.; Nemeczek, C. 2005: Drug committee--an educational police?. Lakartidningen 102(34): 2327-8; Discussion 2238

Allebeck, P. 2005: Drug committees are necessary, according to the SNS reference group. Lakartidningen 102(14): 1070

Jönsson, B. 2005: Drug committees are not necessary--therapeutic recommendations are issued anyway. Lakartidningen 102(28-29): 2085-6: Discussion 290-2

Rabøl, R.; Kampmann, J.Peter.; Christensen, H.R. 2004: Drug committees in Denmark. Status and future challenges. Ugeskrift for Laeger 166(35): 2988-2991

Jönsson, B.; Arvidsson, Göran.; Levin, L-Ake.; Rehnberg, C. 2005: Drug committees should be abolished because the reality has changed. Lakartidningen 102(11): 880

Rane, A. 2006: Drug committees should not recommend "off label" prescriptions. Lakartidningen 103(15-16): 1219

Ohlsson, O. 2004: Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy. Lakartidningen 101(49): 3984-3985

Baker, E.; Newnes, C.; Myatt, H. 2003: Drug companies and clinical psychology. Ethical Human Sciences and Services: An International Journal of Critical Inquiry 5(3): 247-253

Hotvedt, R. 2005: Drug companies and continuing education. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 125(15): 2043

Rai, S. 2005: Drug companies cut costs with foreign clinical trials. New York Times on the Web 2005: C4

Brettingham, M. 2004: Drug companies frame rules to work with NHS. Bmj 329(7459): 189

Cross, M. 2005: Drug companies monitor web chat for adverse reaction reports. Bmj 330(7504): 1347

Christenson, V. 2005: Drug companies offer major discounts to uninsured. Journal of Law Medicine and Ethics: a Journal of the American Society of Law Medicine and Ethics 33(2): 399-403

Dyer, O. 2003: Drug companies pay out millions after overcharging Medicaid. Bmj 326(7395): 900

Rollet, J. 2003: Drug companies respond to NP boycott threat. Advance for Nurse Practitioners 11(5): 17

Walgate, R. 2003: Drug companies should cut prices for developing countries, says G8 report. Bulletin of the World Health Organization 81(1): 72-73

Burton, B. 2005: Drug companies told that sponsoring patients' groups might help win approval for their products. Bmj 331(7529): 1359

Anonymous 2003: Drug companies want to inform patients. Bmj 326(7402): 1286

Jack, A. 2006: Drug companies' lobbying of ministers has little effect on NICE. Bmj 333(7571): 719

Rapaport, M.J.; Franzblau, M. 2007: Drug companies, dermatologists, and the patient. Journal of the American Academy of Dermatology 56(2): 333-334

Tuorto, S.; Chan, M.-K.; Adusumilli, P.S. 2004: Drug companies, doctors and disclosures. National Medical Journal of India 17(4): 215-216

Waechter, F. 2003: Drug company accused of breaking advertising regulations. Bmj 326(7399): 1106

Dyer, O. 2003: Drug company and pharmacy send unsolicited samples of Prozac to Florida residents. Bmj 327(7421): 950

Bassell, K. 2004: Drug company charity programs. Health Affairs 23(3): 288

Zarocostas, J. 2006: Drug company chief urges faster introduction of new vaccines in poor nations. Bmj 333(7557): 11

Eaton, L. 2005: Drug company chiefs accept the need for more openness. Bmj 330(7484): 163

Sheldon, T. 2003: Drug company employee who queried trial wins appeal. Bmj 327(7410): 307

Kondro, W.; Sibbald, B. 2004: Drug company experts advised staff to withhold data about SSRi use in children. Cmaj: Canadian Medical Association Journal 170(5): 783

Kmietowicz, Z. 2004: Drug company influence extends to nurses, pharmacists, and patient groups. Bmj 329(7476): 1206

Kmietowicz, Z. 2005: Drug company is censured for offering perks to prescribing nurses. Bmj 330(7498): 984

Eaton, L. 2005: Drug company is reprimanded by UK regulator. Bmj 330(7496): 865

Parry, J. 2004: Drug company pulls out of Chinese lawsuit over diabetes drug. Bmj 329(7464): 476

Charatan, F. 2004: Drug company raises US price of AIDS drug five-fold. Bmj 328(7446): 974

Christensen, R.C.; Garces, L.K. 2004: Drug company representatives and psychiatrists. Psychiatric Services 55(8): 944

Lenzer, J. 2007: Drug company seeks to suppress internal memos. Bmj 334(7584): 59

Moynihan, R. 2003: Drug company sponsorship of education could be replaced at a fraction of its cost. Bmj 326(7400): 1163

Gibson, L. 2004: Drug company sues Spanish bulletin over fraud claim. Bmj 328(7433): 188

Moynihan, R. 2004: Drug company targets US state health officials. Bmj 328(7435): 306

Pincock, S. 2003: Drug company to offer new malaria drug cheaply in Africa. Bmj 327(7411): 360

Nafeev, A.A. 2004: Natural foci of leptospirosis and hemorrhagic fever with renal syndrome on the territory of the Ulyanovsk region. Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 6(3): 119-120

Regier, L.; Jensen, B.; Laubscher, T. 2004: Drug comparison charts. Detailed, objective, comparative drug information. Canadian Family Physician Medecin de Famille Canadien 50: 1687-1689

Trissel, L.A.; Xu, Q.A.; Baker, M. 2006: Drug compatibility with new polyolefin infusion solution containers. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 63(23): 2379-2382

Hansson Scherman, M.; Löwhagen, O. 2004: Drug compliance and identity: reasons for non-compliance. Experiences of medication from persons with asthma/allergy. Patient Education and Counseling 54(1): 3-9

Schneider, M.-P.; Locca, J.-F.; Bugnon, O.; Conzelmann, M. 2006: Drug compliance in the elderly: determinants and support. Revue Medicale Suisse 2(56): 664

Asadi-Pooya, A.A. 2005: Drug compliance of children and adolescents with epilepsy. Seizure 14(6): 393-395

Atella, V.; Peracchi, F.; Depalo, D.; Rossetti, C. 2006: Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients. Health Economics 15(9): 875-892

Papich, M.G. 2005: Drug compounding for veterinary patients. Aaps Journal 7(2): E281-E287

Busuttil, A. 1994: Drug concealment in custody deaths--two cases. Journal of Clinical Forensic Medicine 1(1): 35-37

Chen, J.-H.; Yang, Y.-M.; Li, K.-Z.; Ling, R.; Yao, Q.; Yang, H. 2005: Drug concentration in axillary lymph nodes of patients with breast cancer after lymphatic chemotherapy. Ai Zheng 24(4): 494-497

Alderman, J.; Wolkow, R.; Fogel, I.M. 2006: Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. Journal of Child and Adolescent Psychopharmacology 16(1-2): 117-129

Chen, J.; Wang, L.; Yao, Q.; Ling, R.; Li, K.; Wang, H. 2004: Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Research: Bcr 6(4): R474-R477

Alonso Castillo, M.M.; Caufield, C.; Gómez Meza, M.V. 2005: Drug consumption and occupational violence in working women of Monterrey, N. L., Mexico. Revista Latino-Americana de Enfermagem 13(Special Issue): 1155-1163

Kubesová, H.; Holík, J.; Weber, P.; Polcarová, V.; Matejovský, J.; Mazalová, K.; Slapák, J. 2006: Drug consumption and risks of polypharmacotherapy in elderly population. Casopis Lekaru Ceskych 145(9): 708-711

Musayón, Y.; Caufield, C. 2005: Drug consumption and violence in female work Zapallal--Lima/Peru. Revista Latino-Americana de Enfermagem 13(Special Issue): 1185-1193

Skouroliakou, M.; Kani, C.; Kompogiorgas, S.; Kontozamanis, V. 2005: Drug consumption during the 2004 Olympics: the special Olympic Pharmacy. Pharmacy World and Science: Pws 27(6): 478-479

Kimber, J.; Dolan, K.; van Beek, I.; Hedrich, D.; Zurhold, H. 2003: Drug consumption facilities: an update since 2000. Drug and Alcohol Review 22(2): 227-233

Esengen, S.; Seçkin, U.; Borman, P.; Bodur, H.; Kutsal, Y.G.; Yücel, M. 2000: Drug consumption in a group of elderly residents of a nursing home: relationship to cognitive impairment and disability. Journal of the American Medical Directors Association 1(5): 197-201

Van der Poel, A.; Barendregt, C.; van de Mheen, D. 2003: Drug consumption rooms in rotterdam: an explorative description. European Addiction Research 9(2): 94-100

Weber, W.W.; Grossman, M.; Thom, J.V.; Sax, J.; Chan, J.J.; Duffy, M.P. 1963: Drug contamination with diethylstilbestrol. Outbreak of precocious puberty due to contaminated isonicotinic acid hydrazide (INH). New England Journal of Medicine 268: 411-415

Paape, W. 1960: Drug control and supply in the People's Republic of Hungary. Die Pharmazie 15: 102-105

Zhen, L.Hui. 2004: Drug control authorities in China. Annals of PharmacoTherapy 38(2): 346-350

Delini, A. 1954: Drug control in Belgium. Arhiv Za Farmaciju 4(2-3): 57-60

Harris, M.F. 1957: Drug control in a small hospital. Canadian Hospital 34(9): 42

Paape, W. 1955: Drug control in the German Democratic Republic. Ceskoslovenska Farmacie 4(5): 217-218

Larrick, G.P. 1961: Drug control in the United States. Pediatrics 27: 480-484

Masters, D.H. 1959: Drug control of the dental salivary problem. Oral Surgery Oral Medicine and Oral Pathology 12(2): 229-233

Nelson, K.R. 1961: Drug control standards for nursing homes. Hospitals 35: 75-78

Seidlein, H.J.; Seidlein, K. 1960: Drug control within the stationary structure of public health. Pharmazeutische Praxis 7: 146-147

Zarubina, I.V. 2003: Drug correction of behavioral reactions and metabolic disorders in rats with craniocerebral trauma. Bulletin of Experimental Biology and Medicine 136(1): 56-58

Chicherina, E.N.; Malykh, S.V. 2003: Drug correction of myocardial ischemia in patients with chronic obstructive bronchitis. Problemy Tuberkuleza i Boleznei Legkikh 2003(11): 19-22

Anonymous 2003: Drug cost. States concerned about Fuzeon. Aids Policy and Law 18(7): 5

Rapp, R.P.; Evans, M.E.; Martin, C.; Ofotokum, I.; Empey, K.L.; Armitstead, J.A. 2004: Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital. Current Medical Research and Opinion 20(4): 469-476

Gumbs, P.D.; Verschuren, W.M.Monique.; Mantel-Teeuwisse, A.K.; de Wit, A.G.; Hofman, A.; Trienekens, P.H.; Stricker, B.H.Ch.; de Boer, A.; Klungel, O.H. 2006: Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. Drugs and Aging 23(9): 733-741

Boersma, C.; Klok, R.M.; Bos, J.M.; Naunton, M.; van den Berg, P.B.; de Jong-van den Berg, L.T.W.; Postma, M.J. 2005: Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands. Applied Health Economics and Health Policy 4(3): 191-196

Anonymous 2005: Drug costs finally slowing, but noncompliance still an issue. Capitation Rates and Data 10(6): 66-72

Fuller, S. 2003: Drug costs in Canada. Health Affairs 22(4): 259

Rabøl, R.; Kolbye, A.; Andersen, S.Ejdrup. 2003: Drug costs in departments of internal medicine. An analysis of costs for patients and departments. Ugeskrift for Laeger 165(15): 1565-1568

Berggren, F. 2003: Drug costs should be based on health economic benefits. a new law on drug benefits requires studies of health economic effects. Lakartidningen 100(30-31): 2446-2448

Jones, D.; Cheesbrough, J. 2005: Drug costs. Antibiotic pharmacist saves 10 pounds sterling per patient per day. Health Service Journal 115(5948): 30

Anonymous 2004: Drug costs: research and development costs: the great illusion. Prescrire International 13(69): 32-36

Damase-Michel, C.; Vié, C.él.; Lacroix, I.; Lapeyre-Mestre, M.; Montastruc, J.L. 2004: Drug counselling in pregnancy: an opinion survey of French community pharmacists. Pharmacoepidemiology and Drug Safety 13(10): 711-715

Bean, P. 1998: Drug courts and drug treatment. Journal of Clinical Forensic Medicine 5(4): 172-175

Tyuse, S.W.; Linhorst, D.M. 2005: Drug courts and mental health courts: implications for social work. Health and Social Work 30(3): 233-240

Cooper, C.S. 2003: Drug courts: current issues and future perspectives. Substance use and Misuse 38(11-13): 1671-1711

Wiseman, C.M. 2005: Drug courts: framing policy to ensure success. International Journal of Offender Therapy and Comparative Criminology 49(3): 235-238

Kapur, V.; Basu, K. 2005: Drug coverage in Canada: who is at risk?. Health Policy 71(2): 181-193

Anonymous 2003: Drug coverage on opportunistic infections down since 1997. Aids Policy and Law 18(4): 5

Sharma, R.; Liu, H.; Wang, Y. 2003: Drug coverage, utilization, and spending by Medicare beneficiaries with heart disease. Health Care Financing Review 24(3): 139-156

Joranson, D.E.; Gilson, A.M. 2005: Drug crime is a source of abused pain medications in the United States. Journal of Pain and Symptom Management 30(4): 299-301

Edwards, P. 2005: Incidentally. British Journal of Perioperative Nursing: the Journal of the National Association of Theatre Nurses 15(11): 460-461

Dreyfus, B. 1959: Drug cytopenia of allergic origin. La Presse Medicale 67: 1464-1466

Best, D.; Havis, S.; Strathdee, G.; Keaney, F.; Manning, V.; Strang, J. 2004: Drug deaths in police custody: is dual diagnosis a significant factor?. Journal of Clinical Forensic Medicine 11(4): 173-182

Darling, H.F. 1959: Drug delirium due to meprobamate; a case report. Diseases of the Nervous System 20(5 Part 1): 225

Sperling, I.L. 1951: Drug delirium due to pyribenzamine. Report of a case with recovery. Journal of the Medical Society of new Jersey 48(4): 166

Furness, G. 2004: Drug delivery - latest technologies and partnerships. Idrugs: the Investigational Drugs Journal 7(2): 133-135

Su, Y.; Sinko, P.J. 2006: Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it?. Expert Opinion on Drug Delivery 3(3): 419-435

Cevc, G. 1997: Drug delivery across the skin. Expert Opinion on Investigational Drugs 6(12): 1887-1937

Iqbal, S.; Ritson, S.; Prince, I.; Denyer, J.; Everard, M.L. 2004: Drug delivery and adherence in young children. Pediatric Pulmonology 37(4): 311-317

Cucullo, L.; Aumayr, B.; Rapp, E.; Janigro, D. 2005: Drug delivery and in vitro models of the blood-brain barrier. Current Opinion in Drug Discovery and Development 8(1): 89-99

Kompella, U.B. 1999: Drug delivery applications of supercritical fluid technology. Idrugs: the Investigational Drugs Journal 2(1): 33-34

Drews, F.A.; Syroid, N.; Agutter, J.; Strayer, D.L.; Westenskow, D.R. 2006: Drug delivery as control task: improving performance in a common anesthetic task. Human Factors 48(1): 85-94

Speck, U.; Scheller, B.; Abramjuk, C.; Bernhardt, U. 2005: Drug delivery by angiographic contrast media: inhibition of restenosis. Academic Radiology 12(Suppl 1): S14-S17

Zarif, L. 2005: Drug delivery by lipid cochleates. Methods in Enzymology 391: 314-329

Cavallaro, G.; Pierro, P.; Palumbo, F.Salvatore.; Testa, F.; Pasqua, L.; Aiello, R. 2004: Drug delivery devices based on mesoporous silicate. Drug Delivery 11(1): 41-46

Byron, P.R. 2004: Drug delivery devices: issues in drug development. Proceedings of the American Thoracic Society 1(4): 321-328

Bhatt, P.P. 2005: Drug delivery for optimised products: from product life-cycle management to first-generation product concepts. Expert Opinion on Drug Delivery 2(1): 1-2

Yasukawa, T.; Ogura, Y.; Kimura, H.; Sakurai, E.; Tabata, Y. 2006: Drug delivery from ocular implants. Expert Opinion on Drug Delivery 3(2): 261-273

Mustata, G.; Dinh, S.M. 2005: Drug delivery global summit--evaluating emerging technologies. Expert Opinion on Drug Delivery 2(1): 185-187

Aigner, T.; Gerwin, N. 2006: Drug delivery in degenerative joint disease. Advanced Drug Delivery Reviews 58(2): 123-124

Abramson, S. 2006: Drug delivery in degenerative joint disease: where we are and where to go?. Advanced Drug Delivery Reviews 58(2): 125-127

Saltzman, M.; Desai, T. 2006: Drug delivery in the BME curricula. Annals of biomedical engineering 34(2): 270-275

Menei, P.; Montero-Menei, C.; Venier, M.-C.; Benoit, J.-P. 2005: Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opinion on Drug Delivery 2(2): 363-376

Zderic, V.; Clark, J.I.; Vaezy, S. 2004: Drug delivery into the eye with the use of ultrasound. Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine 23(10): 1349-1359

Wang, D.; Brömme, D. 2005: Drug delivery strategies for cathepsin inhibitors in joint diseases. Expert Opinion on Drug Delivery 2(6): 1015-1028

Coviello, T.; Matricardi, P.; Alhaique, F. 2006: Drug delivery strategies using polysaccharidic gels. Expert Opinion on Drug Delivery 3(3): 395-404

Mathews, A.Stella.; Ha, C-Sik.; Cho, W-Jei.; Kim, I. 2006: Drug delivery system based on covalently bonded poly[N-isopropylacrylamide-co-2-hydroxyethylacrylate]-based nanoparticle networks. Drug Delivery 13(4): 245-251

Eshita, Y.; Uemoto, S.; Tabata, Y.; Sakamoto, S.; Egawa, H.; Hashida, T.; Inui, K.; Tanaka, K. 2005: Drug delivery system using microspheres that contain tacrolimus in porcine small bowel transplantation. Transplant International: Official Journal of the European Society for Organ Transplantation 17(12): 841-847

Erdine, S.; De Andrés, Jé. 2006: Drug delivery systems. Pain Practice: the Official Journal of World Institute of Pain 6(1): 51-57

Lee, V.H.L. 2005: Drug delivery systems for treating orphan retinal diseases. Retina 25(8 Suppl): S44-S45

Yasukawa, T.; Ogura, Y.; Tabata, Y.; Kimura, H.; Wiedemann, P.; Honda, Y. 2004: Drug delivery systems for vitreoretinal diseases. Progress in Retinal and Eye Research 23(3): 253-281

Wertheimer, A.I.; Santella, T.M.; Finestone, A.J.; Levy, R.A. 2005: Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Advances in Therapy 22(6): 559-577

Farokhzad, O.C.; Dimitrakov, J.D.; Karp, J.M.; Khademhosseini, A.; Freeman, M.R.; Langer, R. 2006: Drug delivery systems in urology--getting "smarter". Urology 68(3): 463-469

Nakayama, M.; Okano, T. 2005: Drug delivery systems using nano-sized drug carriers. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(7): 935-940

Puisieux, F.; Seiller, M.; Devissaguet, J.-P. 2006: Drug delivery systems: a real therapeutic advance. Annales Pharmaceutiques Francaises 64(4): 219-259

Donawa, M. 2000: Drug delivery systems: avoiding the pitfalls. Medical Device Technology 11(6): 28-31

Kaş, H.S.üh. 2004: Drug delivery to brain by microparticulate systems. Advances in Experimental Medicine and Biology 553: 221-230

Ningaraj, N.S. 2006: Drug delivery to brain tumours: challenges and progress. Expert Opinion on Drug Delivery 3(4): 499-509

Isaza, R.; Hunter, R.P. 2004: Drug delivery to captive Asian elephants - treating Goliath. Current Drug Delivery 1(3): 291-298

Aliautdin, R.N.; Kreuter, J.; Kharkevich, D.A. 2003: Drug delivery to the brain with nanoparticles. Eksperimental'naia i Klinicheskaia Farmakologiia 66(2): 65-68

Müller, R.H.; Keck, C.M. 2004: Drug delivery to the brain--realization by novel drug carriers. Journal of Nanoscience and Nanotechnology 4(5): 471-483

Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S.P. 2003: Drug delivery to the central nervous system: a review. Journal of Pharmacy and Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences Societe Canadienne des Sciences Pharmaceutiques 6(2): 252-273

Tamura, T.; Kita, T.; Nakagawa, T.; Endo, T.; Kim, T-Soo.; Ishihara, T.; Mizushima, Y.; Higaki, M.; Ito, J. 2005: Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope 115(11): 2000-2005

Staecker, H.; Brough, D.E.; Praetorius, M.; Baker, K. 2004: Drug delivery to the inner ear using gene therapy. Otolaryngologic Clinics of North America 37(5): 1091-1108

Newman, S.P. 2003: Drug delivery to the lungs from dry powder inhalers. Current Opinion in Pulmonary Medicine 9(Suppl 1): S17-S20

Duvvuri, S.; Majumdar, S.; Mitra, A.K. 2003: Drug delivery to the retina: challenges and opportunities. Expert Opinion on Biological Therapy 3(1): 45-56

Friend, D.R. 2004: Drug delivery to the small intestine. Current Gastroenterology Reports 6(5): 371-376

Streubel, A.; Siepmann, J.; Bodmeier, R. 2006: Drug delivery to the upper small intestine window using gastroretentive technologies. Current Opinion in Pharmacology 6(5): 501-508

Burt, H.; Leroux, J-Christophe.; Amsden, B.; Uludag, H. 2007: Drug delivery: a Canadian perspective. 25 years of innovative drug delivery research. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 65(3): Iii

Eisch, A.J.; Mandyam, C.D. 2004: Drug dependence and addiction, II: Adult neurogenesis and drug abuse. American Journal of Psychiatry 161(3): 426

Volkow, N. 2004: Drug dependence and addiction, III: Expectation and brain function in drug abuse. American Journal of Psychiatry 161(4): 621

Self, D. 2004: Drug dependence and addiction: neural substrates. American Journal of Psychiatry 161(2): 223

Pajulo, M. 2003: Drug dependency and early phase mother-child interaction. Duodecim; Laaketieteellinen Aikakauskirja 119(14): 1335-1342

Lengauer, E. 2007: Drug dependent adolescents have Alzheimer disease-like brains. Kinderkrankenschwester: Organ der Sektion Kinderkrankenpflege 26(1): 37

Oizumi, Y. 2003: Drug design and animal experimentation. Experimental Animals 52(1): Suppl: 18-22

Wiser, M.F. 2001: Drug design strategies. Idrugs: the Investigational Drugs Journal 4(1): 53-55

Honey, K. 2007: Drug designed to raise HDL levels falls down. Journal of Clinical Investigation 117(2): 282

Ferber, D. 2003: Drug designers learn their ABC. Drug Discovery Today 8(21): 960-961

Tuma, R.S. 2003: Drug designers seek a structural solution. Drug Discovery Today 8(22): 1012

Roses, A.D.; Pangalos, M.N. 2003: Drug development and Alzheimer disease. American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry 11(2): 123-130

Crowley, W.F. 2007: Drug development and clinical research in the UK. Lancet 369(9557): 174-175

Calabrese, E.J.; Staudenmayer, J.W.; Stanek, E.J. 2006: Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Current Opinion in Drug Discovery and Development 9(1): 117-123

Kleiman, J.H. 2003: Drug development and the heart hospital. American Heart Hospital Journal 1(2): 188-191

Shah, R.R. 2004: Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). British Journal of Clinical Pharmacology 58(5): 452-469

Rupp, H. 2004: Drug development based on functional genomics of overloaded cardiomyocytes: a novel approach for preventing progression of heart failure. Journal of Muscle Research and Cell Motility 25(8): 608-609

Jeppsson, A. 2006: Drug development costs are overstated by the industry. Lakartidningen 103(9): 663

Carson, W.H.; Kitagawa, H. 2004: Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacology Bulletin 38(1): 38-45

Coté, C.J.; Alexander, J. 2003: Drug development for children: the past, the present, hope for the future. Paediatric Anaesthesia 13(4): 279-283

Tonner, P.H. 2005: Drug development in anaesthesia: go create!. Current Opinion in Anaesthesiology 18(4): 383-385

Kilpatrick, G.J.; Tilbrook, G.S. 2006: Drug development in anaesthesia: industrial perspective. Current Opinion in Anaesthesiology 19(4): 385-389

Bain, L.J. 2006: Drug development in critical times. Neurorx: the Journal of the American Society for Experimental Neurotherapeutics 3(4): 540-543

Cohen, S.J.; Meropol, N.J. 2002: Drug development in pancreatic cancer: finally, biology begets therapy. International Journal of Gastrointestinal Cancer 32(2-3): 91-106

Stinchcombe, T.E.; Socinski, M.A. 2004: Drug development in patients with advanced non-small cell lung cancer and poor performance status. Seminars in Oncology 31(6 Suppl 11: 21-26

Preskorn, S.H. 2001: Drug development in psychiatry and genomics: from E. coli to man. Journal of Psychiatric Practice 7(6): 415-419

Preskorn, S.H. 2001: Drug development in psychiatry and the human genome project: the explosion in knowledge and potential targets. Journal of Psychiatric Practice 7(5): 336-340

Hall, E.D. 2003: Drug development in spinal cord injury: what is the FDA looking for?. Journal of Rehabilitation Research and Development 40(4 Suppl 1: 81-91

Wong, J. 2006: Drug development in the Pacific Rim. Clinical Advances in Hematology and Oncology: H&o 4(9): 670-672

Novack, G.D. 2002: Drug development issues in pharmacological treatments for dry eye. Advances in Experimental Medicine and Biology 506(Part B): 1117-1120

Rajadhyaksha, G.C. 2003: Drug development process and overview of GCP. Journal of the Association of Physicians of India 51: 115-118

Schneider, L.S. 2005: Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment. Alzheimer Disease and Associated Disorders 19(4): 279-283

Alper, J. 2003: Drug development. Biotech thinking comes to academic medical centers. Science 299(5611): 1303-1305

Marx, J. 2006: Drug development. Drugs inspired by a drug. Science 311(5759): 322-325

Couzin, J. 2005: Drug development. Lupus drug company asks FDA for second chance. Science 307(5711): 835

Aronson, J.K. 2005: Drug development: more science, more education. British Journal of Clinical Pharmacology 59(4): 377-378

Miwa, H.; Hiwatani, Y.; Kondo, T. 2007: Drug discarding: a problematic therapeutic event in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 22(2): 293

Traynor, K. 2004: Drug discount cards for Medicare beneficiaries to debut this year. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 61(3): 224; 227

Mullins, C.D. 2003: Drug discounts for the uninsured. Clinical Therapeutics 25(6): 1784-1785

Kennedy, D. 2004: Drug discovery. Science 303(5665): 1729

Terricabras, E.; Benjamim, C.; Godessart, N. 2004: Drug discovery and chemokine receptor antagonists: eppur si muove!. Autoimmunity Reviews 3(7-8): 550-556

Satzinger, G. 2001: Drug discovery and commercial exploitation. Drug News and Perspectives 14(4): 197-207

Triggle, D.J. 2007: Drug discovery and delivery in the 21st century. Medical Principles and Practice: International Journal of the Kuwait University Health Science Centre 16(1): 1-14

Edwards, C.K. 2004: Drug discovery and development for inflammatory diseases. Expert Opinion on Therapeutic Targets 8(2): 151-163

Hooft, R. 2003: Drug discovery and development for metabolic diseases. Drug Discovery Today 8(23): 1064-1066

Nyigo, V.A.; Malebo, H.M. 2005: Drug discovery and developments in developing countries: bottlenecks and way forward. Tanzania Health Research Bulletin 7(3): 154-158

Verkman, A.S. 2004: Drug discovery and epithelial physiology. Current Opinion in Nephrology and Hypertension 13(5): 563-568

Katsuma, S.; Tsujimoto, G. 2002: Drug discovery and personalized medicine based on the functional genomics. Seikagaku. Journal of Japanese Biochemical Society 74(12): 1441-1451

Demonacos, C.; La Thangue, N.B. 2003: Drug discovery and the p53 family. Progress in Cell Cycle Research 5: 375-382

Mongin-Bulewski, C. 2002: Drug discovery case histories. Idrugs: the Investigational Drugs Journal 5(9): 902-904

Rogatsky, I. 2003: Drug discovery for inflammatory diseases. Expert Opinion on Biological Therapy 3(6): 1001-1004

Miyata, K.; Ito, H. 2006: Drug discovery for irritable bowel syndrome. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 128(2): 104-107

Chin, Y-Won.; Balunas, M.J.; Chai, H.Byung.; Kinghorn, A.Douglas. 2006: Drug discovery from natural sources. Aaps Journal 8(2): E239-E253

Willemsen-Swinkels, S.H.N.; Buitelaar, J.K. 2004: Drug discovery in autism: the need for a developmental context. Drug Discovery Today 9(11): 473

Geerts, H.; Trojanowski, J.Q.; Lee, V.M-Y. 2005: Drug discovery in neurodegenerative diseases. Science of Aging Knowledge Environment: Sage Ke 2005(6): Pe4

Preskorn, S.H. 2001: Drug discovery in psychiatry: drilling down on the target of interest. Journal of Psychiatric Practice 7(4): 267-272

Lando, D. 2004: Drug discovery in the HIF pathway: where do we go now?. Drug Discovery Today 9(18): 782-783

Miyata, K. 2005: Drug discovery in the fields of urology: tamsulosin and solifenacin. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 126(5): 341-345

Kéri, Görgy.; Székelyhidi, Z.; Bánhegyi, Péter.; Varga, Zán.; Hegymegi-Barakonyi, Bálint.; Szántai-Kis, C.; Hafenbradl, D.; Klebl, B.; Muller, G.; Ullrich, A.; Erös, Dániel.; Horváth, Zán.; Greff, Zán.; Marosfalvi, Jö.; Pató, János.; Szabadkai, Ián.; Szilágyi, Ió.; Szegedi, Z.; Varga, Ián.; Wáczek, F.; Orfi, László. 2005: Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Assay and Drug Development Technologies 3(5): 543-551

Tan, P. 2005: Drug discovery in the lion city. Drug Discovery Today 10(17): 1143-1144

Xie, W.; Uppal, H. 2003: Drug discovery perspective of chemical-driven mouse mutagenesis. Drug Discovery Today 8(5): 199

Weinmann, H.; Metternich, R. 2005: Drug discovery process for kinase inhibitors. Chembiochem: a European Journal of Chemical Biology 6(3): 455-459

Workman, P. 2004: Drug discovery strategies: technologies to accelerate translation from target to drug. Journal of ChemoTherapy 16 Suppl. 4: 13-15

Braddock, M. 2004: Drug discovery summit on anti-inflammation and immune diseases. Immune-mediated diseases--second international meeting. 8-9 March 2004, Baltimore, MD, USA. IDrugs: the investigational drugs journal 7(5): 436-440

Zhou, B-Bing.S.; Sausville, E.A. 2003: Drug discovery targeting Chk1 and Chk2 kinases. Progress in Cell Cycle Research 5: 413-421

Jones, E.; Mongin-Bulewski, C. 2002: Drug discovery technology 2002. Start-up showcase and structure-based drug design. Idrugs: the Investigational Drugs Journal 5(9): 894-895

Kubinyi, H. 2001: Drug discovery technology. Start-up companies. Idrugs: the Investigational Drugs Journal 4(7): 783-787

Zernov, V.V.; Balakin, K.V.; Ivaschenko, A.A.; Savchuk, N.P.; Pletnev, I.V. 2003: Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. Journal of Chemical Information and Computer Sciences 43(6): 2048-2056

Shaffer, C. 2005: Drug discovery veers off target. Drug Discovery Today 10(22): 1489

Ross-Macdonald, P. 2007: Drug discovery without a molecular target: the road less traveled. Expert Review of Molecular Diagnostics 7(1): 1-4

Couzin, J. 2005: Drug discovery. Magnificent obsession. Science 307(5716): 1712-1715

Kulmatycki, K.M.; Jamali, F. 2006: Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response. Journal of Pharmacy and Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences Societe Canadienne des Sciences Pharmaceutiques 9(3): 292-306

Kulmatycki, K.M.; Jamali, F. 2005: Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. Journal of Pharmacy and Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences Societe Canadienne des Sciences Pharmaceutiques 8(3): 602-625

Gardlund, W. 1953: Drug dispensing. Svenska Lakartidningen 50(34): 1747-1748

Andersen, S.E. 2006: Drug dispensing errors. Ugeskrift for Laeger 168(48): 4185-4188

Penna, P. 2005: Drug dispensing patterns. Managed Care Interface 18(7): 37-38

Ward, R.M. 2006: Drug disposition in the late preterm ("near-term") newborn. Seminars in Perinatology 30(1): 48-51

Tanaka, T.; Sakaguchi, H.; Anai, H.; Kichikawa, K. 2006: Drug distribution and alteration of blood flow for pancreatic arterial infusion chemotherapy. Nihon Rinsho. Japanese Journal of Clinical Medicine 64(Suppl 1): 264-269

La Vecchia, C.; Franceschi, S.; Apolone, G. 2003: Drug distribution and expenditure: the issue of epoetin in Italy. European Journal of Public Health 13(4): 367

Li, Y.; Liu, B.-w.; Du, W.-l.; Song, Z.-c.; Zhao, Q.; Fan, L.-q.; Yang, J.-q.; Li, Q.-j.; Wang, M.-x.; Jiao, Z.-k.; Zhang, Z.-d. 2004: Drug distribution in gastric cancer and adjacent tissues by preoperative intraperitoneal chemotherapy with Co-fluorouracil liposome. Zhonghua Zhong Liu Za Zhi 26(10): 638-640

Devers, G. 2003: Drug distribution in nursing homes, a green light for nurses' aides. Soins. Gerontologie 43: 41-43

Di Paolo, A.; Bocci, G. 2007: Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Current Oncology Reports 9(2): 109-114

Lantos, R.L. 1959: Drug distribution is the pharmacy's job. Modern Hospital 92(2): 104 Passim

Lehmann, S.ör.; Rane, A. 2004: Drug distribution, resistance to cytostatics and disease pathogenesis: many roles of ABC proteins. Lakartidningen 101(4): 282-287

Freeman, J. 2004: Drug diverting patients and prescription monitoring--both sides of the debate. Iowa Medicine: Journal of the Iowa Medical Society 94(5): 10-11

Aymanns, C.; Keller, F. 2004: Drug dosage in renal failure -- traps and aids. Medizinische Klinik 99(10): 613

Flammiger, A.; Maibach, H. 2006: Drug dosage in the elderly: dermatological drugs. Drugs and Aging 23(3): 203-215

Varlamov, S.E.; Bolotin, N.B. 2004: Drug dosing device. Meditsinskaia Tekhnika 2: 16-18

Veltri, M.A.; Neu, A.M.; Fivush, B.A.; Parekh, R.S.; Furth, S.L. 2004: Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients. Paediatric Drugs 6(1): 45-65

Gabardi, S.; Abramson, S. 2005: Drug dosing in chronic kidney disease. Medical Clinics of North America 89(3): 649-687

Colace, C. 2006: Drug dreams in cocaine addiction. Drug and Alcohol Review 25(2): 177

Froitzheim, G. 1952: Drug eczema. Medizinische Klinik 47(38): 1247-1248

Koch, R. 1963: Drug effect and radiation injury. Hippokrates 34: 125-131

Hu, Y.; Wang, Z.; Song, Y.; Deng, C. 2002: Drug effect comparison of Rhubarb extract by the technology free of heating and the extracts form crude Rhubarb and from prepared Rhubarb. Zhong Yao Cai 25(12): 893-895

Schlossmann, H.A. 1949: Drug effects and aging. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie 208(2-3): 219-221

Kuhnau, J. 1956: Drug effects and intermediary metabolism. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie 228(1-2): 81-93

Lindemann, E.; von FELSINGER, J. 1961: Drug effects and personality theory. Psychopharmacologia 2: 69-92

Lasagna, L. 1956: Drug effects as modified by aging. Journal of Chronic Diseases 3(6): 567-574

Blume, W.T. 2006: Drug effects on EEG. Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society 23(4): 306-311

Alshuaib, W.B.; Cherian, S.P.; Hasan, M.Y.; Fahim, M.A. 2003: Drug effects on calcium homeostasis in mouse CA1 hippocampal neurons. International Journal of Neuroscience 113(10): 1317-1332

Van Alphen, G.W.; Robinette, S.L.; Macri, F.J. 1962: Drug effects on ciliary muscle and choroid preparations in vitro. Archives of Ophthalmology 68: 81-93

Siest, G.; Dawkins, S.J.; Galteau, M.M. 1983: Drug effects on clinical laboratory tests. Journal of Pharmaceutical and Biomedical Analysis 1(3): 247-257

Abdulian, D.H.; Martin, W.R.; Unna, K.R. 1959: Drug effects on interneurones: effects of central nervous system depressants on spinal cord reflexes. Research Publications - Association for Research in Nervous and Mental Disease 37: 72-84; Discussion: 84-85

Scully, C. 2003: Drug effects on salivary glands: dry mouth. Oral Diseases 9(4): 165-176

Cook, L.; Kelleher, R.T. 1962: Drug effects on the behavior of animals. Annals of the new York Academy of Sciences 96: 315-335

Towler, M.L.; Beall, B.D.; King, J.B. 1962: Drug effects on the electroencephalographic pattern, with specific consideration of diazepam. Southern Medical Journal 55: 832-838

Cassidy, M.J. 2003: Drug effects on the kidney. Practitioner 247(1652): 874-879

Ayalasomayajula, S.P.; Kompella, U.B. 2000: Drug efflux pumps: challenges and opportunities. 14-18 November 1999, New Orleans, LA, USA. IDrugs: the investigational drugs journal 3(2): 148-149

Chen, Y.-J.; Lin, H.; Zhang, X.; Huang, W.; Shi, L.; Wang, D. 2017: Application of 3D-printed and patient-specific cast for the treatment of distal radius fractures: initial experience. 3d Printing in Medicine 3(1): 11

Shellock, F.G.; Forder, J.R. 2005: Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla. Journal of Cardiovascular Magnetic Resonance: Official Journal of the Society for Cardiovascular Magnetic Resonance 7(2): 415-419

Fraser, T.; Johanson, P.; Herlitz, J.; Simonsson, M. 2006: Drug eluting stents are drugs and should be scrutinized as such. Lakartidningen 103(13): 1046

Mayor, S. 2006: Drug eluting stents are safe for licensed indications, FDA panel says. Bmj 333(7581): 1235

Laham, R.J. 2005: Drug eluting stents for everyone and everything?. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 66(4): 512-513

Gershlick, A.H. 2005: Drug eluting stents in 2005. Heart 91(Suppl 3): Iii24-Iii31

Couppié, P.; De Poli, F.; Thalouarn, C.; Fellinger, F.; Hanssen, M.; Dickelé, M.C. 2005: Drug eluting stents in 2005: have the initial expectations been met?. Annales de Cardiologie et d'Angeiologie 54(6): 325-331

Swanson, N.; Gershlick, A.H. 2005: Drug eluting stents in interventional cardiology -- current evidence and emerging uses. Current Drug Targets. Cardiovascular and Haematological Disorders 5(4): 313-321

Machan, L. 2004: Drug eluting stents in the infrainguinal circulation. Techniques in Vascular and Interventional Radiology 7(1): 28-32

Rondan, J.; Lozano, I.; Avanzas, P.; Lopez-Palop, R.; Vegas, J.M.; Moris, C. 2007: Drug eluting stents may not be the answer for myocardial bridges. International Journal of Cardiology 117(2): E76-E78

Lablanche, J.M. 2003: Drug eluting stents, a priceless advance!. Archives des Maladies du Coeur et des Vaisseaux 96(3): 161-162

Groch, L. 2004: Drug eluting stents--end of restenosis?. Vnitrni Lekarstvi 50(Suppl 1): S59-S62

Klein, L.W.; Hodgson, J.M. 2005: Drug eluting stents: case study in the acceptance of a new medical technology. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 64(4): 528-530

Philippe, F.; Dibie, A.; Larrazet, F.; Meziane, T.; Folliguet, T.; Laborde, E. 2005: Drug eluting stents: from evidence based medicine to clinical practice. Annales de Cardiologie et d'Angeiologie 54(4): 201-211

Grube, E.; Gerckens, U.; Müller, R.; Büllesfeld, L. 2002: Drug eluting stents: initial experiences. Zeitschrift für Kardiologie 91(Suppl 3): 44-48

Barthélémy, O. 2004: Drug eluting stents: lessons from registries and literature. Annales de Cardiologie et d'Angeiologie 53(5): 229-233

Sánchez-Rubio Lezcano, J.; Galache Osuna, J.é G.; Calvo Cebollero, I.; Lukic, A.; Diarte de Miguel, J.é A.; Placer Peralta, L.J. 2007: Drug eluting stents: long term results in clinical practice. Comparison between rapamycin and paclitaxel eluting stents. Medicina Clinica 128(6): 211-213

Muldrew, B.L. 2004: Drug enforcement: Controlled Substances Act inapplicable to medicinal marijuana. Journal of Law Medicine and Ethics: a Journal of the American Society of Law Medicine and Ethics 32(2): 371-372

Abeysekera, A.; Bergman, I.J.; Kluger, M.T.; Short, T.G. 2005: Drug error in anaesthetic practice: a review of 896 reports from the Australian Incident Monitoring Study database. Anaesthesia 60(3): 220-227

Preston, R.M. 2004: Drug errors and patient safety: the need for a change in practice. British Journal of Nursing 13(2): 72-78

Yentis, S.M.; Randall, K. 2003: Drug errors in obstetric anaesthesia: a national survey. International Journal of Obstetric Anesthesia 12(4): 246-249

Armitage, G. 2005: Drug errors, qualitative research and some reflections on ethics. Journal of Clinical Nursing 14(7): 869-875

Guy, J.; Persaud, J.; Davies, E.; Harvey, D. 2003: Drug errors: what role do nurses and pharmacists have in minimizing the risk?. Journal of Child Health Care: for Professionals Working with Children in the Hospital and Community 7(4): 277-290

Mori, H.; Yamanaka, K.; Kaketa, M.; Tamada, K.; Hakamada, A.; Isoda, K.-i.; Yamanishi, K.; Mizutani, H. 2004: Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. Journal of Dermatology 31(9): 731-736

Okamoto, O.; Fujiwara, S. 2007: Drug eruption caused by ranitidine hydrochloride (Zantac) which showed a strong reaction in a drug-induced lymphocyte stimulation test. Journal of Dermatology 34(1): 74-79

Matsumura, T.; Watanabe, H.; Batchelor, J.; Sueki, H.; Iijima, M. 2006: Drug eruption caused by the nonionic contrast medium iohexol. "Recall-like phenomenon" appearing on an area previously affected by herpes zoster. Journal of Dermatology 33(10): 705-708

Nagai, Y.; Yamanaka, M.; Nishimura, S.; Nakano, A.; Hasegawa, A.; Ishikawa, O. 2006: Drug eruption due to bosentan in a patient with systemic sclerosis. Modern Rheumatology 16(3): 188-190

Umebayashi, Y.; Enomoto, H.; Ogasawara, M. 2004: Drug eruption due to peplomycin: an unusual form of Stevens-Johnson syndrome with pustules. Journal of Dermatology 31(10): 802-805

Ross, M.S. 1957: Drug eruption from Rauwolfia serpentina. A.M.A. Archives of Dermatology 75(3): 439

Loewenthal, L.J.A. 1952: Drug eruption from paludrine (proguanil) hydrochloride; report of a case. British Journal of Dermatology 64(3): 106-107

Gaul, L.E. 1955: Drug eruption from sulfonamides; minimal oral dose of sulfadiazine, sulfamerazine, and sulfamethazine to detect their sensitivity. A.M.A. Archives of Dermatology 71(6): 740-741

Liu, Q.-y.; Wang, L.-f. 2005: Drug eruption of erythema multiforme caused by amikacin in a case. Zhonghua Er Ke Za Zhi 43(3): 187

Berger, S.S. 1951: Drug eruption treated with cortisone; a case report. Manitoba Medical Review 31(7): 419-421

Puavilai, S.; Noppakun, N.; Sitakalin, C.; Leenutaphong, V.; Wattanakrai, P.; Nakakes, A.; Kulthanan, K.; Asawanonda, P.; Akaraphan, R.; Tresukosol, P.; Suthipinittharm, P.; Somburanasin, P.; Charuwichitratana, S.; Rajatanavin, N. 2005: Drug eruptions at five institutes in Bangkok. Journal of the Medical Association of Thailand 88(11): 1642-1650

Barrock, J.J. 1951: Drug eruptions due to antihistaminics. Wisconsin Medical Journal 50(2): 156-158

Stroud, G.M. 1957: Drug eruptions due to meprobamate. New England Journal of Medicine 256(8): 354-355

Ch'en, C.C.; Ma, S.K. 1957: Drug eruptions due to phenobarbital (luminal): report of 16 cases. Chinese Medical Journal 75(6): 490-499

Nakada, T.; Akiyama, M.; Iijima, M.; Kato, A.; Maibach, H.I. 2006: Drug eruptions to contrast media in Japan. Clinical and Experimental Dermatology 31(3): 361-364

Dickey, R.F. 1960: Drug eruptions. Diagnosis and treatment. Pennsylvania Medical Journal 63: 1646-1658

Kirshbaum, B.A.; Beerman, H.; Stahl, E.B. 1960: Drug eruptions: a review of some of the recent literature. American Journal of the Medical Sciences 240: 512-530

Nigen, S.; Knowles, S.R.; Shear, N.H. 2003: Drug eruptions: approaching the diagnosis of drug-induced skin diseases. Journal of Drugs in Dermatology: Jdd 2(3): 278-299

O'donovan, W.J. 1954: Drug eruptions: old and new. Journal of the Irish Medical Association 35(206): 226-229

Peterkin, G.A.G. 1959: Drug eruptions; their causation and treatment. Postgraduate Medicine 25(1): 2-10

Hollenberg, A. 1961: Drug evaluation and allergy. Allgemeine Homoopathische Zeitung für Wissenschaftliche und Praktische Homoopathie 206: 339-349

San Miguel, M.Teresa.; Vargas, E. 2006: Drug evaluation and approval process in the European Union. Arthritis and Rheumatism 55(1): 12-14

Merlis, S.; Turner, W.J. 1961: Drug evaluation and practical psychiatric therapeutics. JAMA 177: 38-42

Zeng, Q.-y. 2005: Drug evaluation and supreme responsibility of medical practitioners. Zhonghua Nei Ke Za Zhi 44(8): 564-565

Bouvenot, G. 2005: Drug evaluation by the French National Health Authority for reimbursement decisions. Bulletin de l'Academie Nationale de Medecine 189(8): 1683-90; Discussion 1690-1

Kory, R.C.; Townes, A.S.; Mabe, R.E.; Dorris, E.R.; Meneely, G.R. 1955: Drug evaluation in angina pectoris: khellin, heparin, peritrate. American Heart Journal 50(2): 308-321

Reeves, J.E. 1959: Drug evaluation in general practice. Gp 30: 108-109

Behrend, B.; Jaeger, E. 1960: Drug evaluation in industrial medicine. Purposes and procedures. Industrial Medicine and Surgery 29: 319-323

Breitner, C. 1962: Drug evaluation in psychiatry. American Journal of Psychiatry 119: 481-482

Smyth, C.J.; Johnson, R.L.; Clark, G.M. 1959: Drug evaluation in rheumatoid arthritis; a comparative study of aspirin, phenylbutazone, cortisone, prednisone. Postgraduate Medicine 25(3): 315-324

Li Wan Po, A. 2005: Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress. Journal of clinical pharmacy and therapeutics 30(1): 1-4

Geerts, H. 2007: Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. Idrugs: the Investigational Drugs Journal 10(2): 121-133

Taupin, P. 2006: Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID. Idrugs: the Investigational Drugs Journal 9(6): 423-430

Kelland, L. 2007: Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. Current Opinion in Molecular Therapeutics 9(1): 86-91

Shen, L.-J.; Shen, W.-C. 2006: Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers. Current Opinion in Molecular Therapeutics 8(3): 240-248

Rice, L. 2006: Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Current Opinion in Investigational Drugs 7(9): 834-841

Elit, L. 2006: Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer. Idrugs: the Investigational Drugs Journal 9(9): 636-644

Chemmanur, A.T.; Wu, G.Y. 2006: Drug evaluation: Albuferon-alpha--an antiviral interferon-alpha/albumin fusion protein. Current Opinion in Investigational Drugs 7(8): 750-758

Odds, F.C. 2006: Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal. Current Opinion in Investigational Drugs 7(8): 766-772

Eckstein, J.W. 2004: Drug evaluation: Bay-59-8862. Idrugs: the Investigational Drugs Journal 7(6): 575-581

Heading, C.E. 2007: Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Current Opinion in Investigational Drugs 8(1): 71-77

Kent, S.; De Rose, R.; Rollman, E. 2007: Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current Opinion in Investigational Drugs 8(2): 159-167

Doehn, C.; Sommerauer, M.; Jocham, D. 2006: Drug evaluation: Degarelix--a potential new therapy for prostate cancer. Idrugs: the Investigational Drugs Journal 9(8): 565-572

Ondiveeran, H.K.; Fox-Robichaud, A. 2004: Drug evaluation: E-5564. Idrugs: the Investigational Drugs Journal 7(6): 582-590

Kirman, I. 2006: Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Current Opinion in Molecular Therapeutics 8(4): 358-365

Burnett, J.R. 2006: Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Current Opinion in Molecular Therapeutics 8(5): 461-467

Papatheodoridis, G.V.; Manolakopoulos, S. 2006: Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection. Current Opinion in Molecular Therapeutics 8(4): 352-357

De Paulis, T. 2006: Drug evaluation: Lymphoseek - Neoprobe's sentinel lymph node imaging agent for use in cancer patients. Current Opinion in Investigational Drugs 7(12): 1100-1107

Schmitz, G. 2006: Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide. Current Opinion in Molecular Therapeutics 8(6): 547-554

Johnson, A.P. 2007: Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Current Opinion in Investigational Drugs 8(2): 168-173

De Paulis, T. 2007: Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Current Opinion in Investigational Drugs 8(1): 78-86

Hamed, S.A. 2006: Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. Idrugs: the Investigational Drugs Journal 9(11): 783-789

Kigerl, K.; Popovich, P. 2006: Drug evaluation: ProCord - a potential cell-based therapy for spinal cord injury. Idrugs: the Investigational Drugs Journal 9(5): 354-360

Stoeckel, J.; Hay, J.G. 2006: Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic. Current Opinion in Molecular Therapeutics 8(3): 249-260

Gehrmann, M. 2006: Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70. Current Opinion in Investigational Drugs 7(6): 574-580

Burnett, J.R. 2006: Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia. Current Opinion in Investigational Drugs 7(9): 850-856

Burnett, J.R. 2006: Drug evaluation: the MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. Idrugs: the Investigational Drugs Journal 9(7): 495-499

Ding, C. 2006: Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Current Opinion in Investigational Drugs 7(11): 1020-1025

De Paulis, T. 2007: Drug evaluation: Vilazodone--a combined SSRi and 5-HT1A partial agonist for the treatment of depression. Idrugs: the Investigational Drugs Journal 10(3): 193-201

Kuwada, S.K. 2007: Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Current Opinion in Molecular Therapeutics 9(1): 92-98

Billich, A. 2007: Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. Idrugs: the Investigational Drugs Journal 10(1): 53-59

Thabet, M.M.; Huizinga, T.W.J. 2006: Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Current Opinion in Investigational Drugs 7(11): 1014-1019

Temesgen, Z.; Feinberg, J.E. 2006: Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor. Current Opinion in Investigational Drugs 7(8): 759-765

Sablayrolles, S.; Le Grand, B. 2006: Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent. Current Opinion in Investigational Drugs 7(9): 842-849

Galmarini, C.M. 2006: Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. Idrugs: the Investigational Drugs Journal 9(10): 712-722

Marini, P. 2006: Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Current Opinion in Molecular Therapeutics 8(6): 539-546

Addis, A.; Rocchi, F. 2006: Drug evaluation: new requirements and perspectives. Recenti Progressi in Medicina 97(11): 618-625

Giannoukakis, N. 2006: Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications. Current Opinion in Investigational Drugs 7(10): 916-923

Galmarini, C.M. 2006: Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer. Current Opinion in Investigational Drugs 7(6): 565-573

Moore, M.C. 2006: Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity. Current Opinion in Investigational Drugs 7(10): 924-935

John, J.F. 2006: Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. Current Opinion in Molecular Therapeutics 8(5): 455-460

Tomlinson, B. 2006: Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Current Opinion in Investigational Drugs 7(10): 936-945

Roche, M.; Kyriakou, H.; Seiden, M. 2006: Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative. Current Opinion in Investigational Drugs 7(12): 1092-1099

Köhl, J.ör. 2006: Drug evaluation: the C5a receptor antagonist PMX-53. Current Opinion in Molecular Therapeutics 8(6): 529-538

Nutescu, E.A.; Pater, K. 2006: Drug evaluation: the directly activated Factor Xa inhibitor otamixaban. Idrugs: the Investigational Drugs Journal 9(12): 854-865

Galmarini, C.M. 2006: Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer. Current Opinion in Investigational Drugs 7(12): 1108-1115

Kluczyk, A.; Kiyota, T.; Lazar, C.; Popek, T.; Roman, G.; Konishi, Y. 2006: Drug evolution concept in drug design: 2. Chimera method. Medicinal Chemistry 2(2): 175-189

Gertler, H. 1961: Drug exanthem after administration of pyrazole derivatives. Zeitschrift für Arztliche Fortbildung 55: 18-21

Fischer, H.; Kappel, I. 1957: Drug exanthem in the region of Head's zones. Dermatologische Wochenschrift 136(33): 875-880

Gertler, H. 1960: Drug exanthem simulating arteriolitis allergica cutis in severe arterios clerosis. Dermatologische Wochenschrift 141: 369-376

Beer, A.é-M.; Fey, S.; Ciborovius, J.; Knorr, M. 2005: Drug exanthema in connection with trimethoprim and sulfamethoxazole treatment, triggered by leech therapy. Forschende Komplementarmedizin und Klassische Naturheilkunde 12(1): 32-36

Kalász, H.; Antal, Ián. 2006: Drug excipients. Current Medicinal Chemistry 13(21): 2535-2563

Swistak, P.; Błońska-Fajfrowska, B. 2003: Drug expenditures of pensioners in 1997-2000. Wiadomosci Lekarskie 56(1-2): 85-88

Notkin, H.; Rogerson, B.; Davis, W.; Taback, M. 1952: Drug experience in two programs for medical care. Public Health Reports 67(8): 797-801

Heischkel, E. 1955: Drug experiments in medical societies about the middle of the 19th century. Hippokrates 26(17): 536-539

Cohen, A.D.; Bonneh, D.Y.; Reuveni, H.; Vardy, D.A.; Naggan, L.; Halevy, S. 2005: Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Dermato-Venereologica 85(4): 299-303

Rousso, P. 2004: Drug exposure during pregnancy: a differentiated approach. Praxis 93(22): 943-947

Spiller, H.A.; Rogers, J.; Sawyer, T.S. 2007: Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine). Legal Medicine 9(4): 192-195

Flaxman, N. 1951: Drug fatalities. Journal of the American Medical Association 147(5): 377-379

Krasnitz, A. 1953: Drug fever due to administration of isoniazid. American Review of Tuberculosis 68(2): 249-252

Rose, O.A.; Vogl, A.; Turtz, A.I. 1953: Drug fever due to quinidine. New England Journal of Medicine 248(3): 96-98

T'ang, B.H.Y. 1951: Drug fever following the use of para-amino-salicylic acid; a case report. Chinese Medical Journal 69(3-4): 185-186

Laha, P.N.; Singhal, R.N.; Navani, H. 1953: Drug fever, leucocyte counts, erythrocyte sedimentation rate and urine after pyrimethamine (daraprim). Indian Journal of Malariology 7(4): 335-338

Schou, J. 1956: Drug fever; short survey, an original observation, and a case. Ugeskrift for Laeger 118(42): 1231-1236

Pollard, T. 2005: Drug fiasco highlights need for more openness. British journal of community nursing 10(1): 5

Cooper, T. 2003: Drug for Gaucher disease also works as sperm inhibitor. Is the "pill" for the man on its way?. MMW Fortschritte der Medizin 145(7): 22

Anonymous 2004: Drug for moderate to advanced Alzheimer's approved. Mayo Clinic Health Letter 22(2): 4

Anonymous 2005: Drug for "off" episodes of Parkinson's--effective but limited. Mayo Clinic Health Letter 23(7): 4

Guay, D.R.P. 2004: Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder. Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists 19(5): 437-444

Guay, D.R.P. 2003: Drug forecast: memantine, prototype of a new approach to treatment of dementia. Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists 18(7): 625-634

Reilly, P. 1995: Drug formularies--helpful tools for drug education?. Occasional Paper 1995(69): 44-46

Curtiss, F.R. 2004: Drug formulary decisions--evaluating the risks and benefits of hormone replacement therapy. Journal of Managed Care Pharmacy: Jmcp 10(1): 85-86

Thames, G. 2004: Drug forum: making pharmacokinetics clinically useful. Gastroenterology nursing: the official journal of the Society of Gastroenterology Nurses and Associates 27(2): 74-75

Harding, M-Louise. 2005: Drug funding. Hewitt, Herceptin and the 100m pound sterling bill PCTs can't afford to pay. Health Service Journal 115(5985): 12-13

Forster, W. 1959: Drug habit, drug addiction, their hazards and control. Pharmazeutische Zentralhalle für Deutschland 98(3): 118-127

Vitte 1957: Drug hemotoxicities and pharmacodynamics. Journal de Medecine de Bordeaux et du Sud-Ouest 134(1): 113-116

Nathwani, R.A.; Kaplowitz, N. 2006: Drug hepatotoxicity. Clinics in Liver Disease 10(2): 207

Schmidt, E.Z.; Hofmann, P.; Kapfhammer, H.-P.; Bonelli, R.M. 2005: Drug holiday in Huntington's disease. Annals of PharmacoTherapy 39(4): 773

Demoly, P.; Gomes, E.R. 2005: Drug hypersensitivities: definition, epidemiology and risk factors. European Annals of Allergy and Clinical Immunology 37(6): 202-206

Aberer, W. 2005: Drug hypersensitivities: the need for standardization. European Annals of Allergy and Clinical Immunology 37(6): 219-222

Sanz, M.ía.L.; Gamboa, P.M.; García-Avilés, C.; De Weck, A. 2005: Drug hypersensitivities: which room for biological tests?. European Annals of Allergy and Clinical Immunology 37(6): 230-235

Solensky, R. 2006: Drug hypersensitivity. Medical Clinics of North America 90(1): 233-260

Naisbitt, D.J. 2004: Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 194(3): 179-196

Bach, S.; Bircher, A.J. 2005: Drug hypersensitivity reactions: from clinical manifestations to an allergologic diagnosis. European Annals of Allergy and Clinical Immunology 37(6): 213-218

Debarbieux, S.; Deroo-Berger, M.-C.; Grande, S.; Najioullah, F.; Kanitakis, J.; Faure, M.; Claudy, A. 2006: Drug hypersensitivity syndrome associated with a primary HHV6 infection. Annales de Dermatologie et de Venereologie 133(2): 145-147

Tsuruta, D.; Someda, Y.; Sowa, J.; Kobayashi, H.; Ishii, M. 2006: Drug hypersensitivity syndrome caused by minocycline. Journal of Cutaneous Medicine and Surgery 10(3): 131-135

Mohty, R.; Chaby, G.; Pannier, M.; Defossez, C.; Denoeux, J.-P.; Lok, C. 2003: Drug hypersensitivity syndrome induced by leflunomide. Annales de Dermatologie et de Venereologie 130(5): 551-552

Jeandel, P.-Y.; Traissac, T.; Rainfray, M.; Bourdel-Marchasson, I. 2005: Drug hypersensitivity syndrome with lamotrigine two cases in elderly. Presse Medicale 34(7): 516-518

Begon, E.; Roujeau, J.-C. 2004: Drug hypersensitivity syndrome: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Annales de Dermatologie et de Venereologie 131(3): 293-297

Svensson, C.K. 2006: Drug hypersensitivity--where do we stand?. Aaps Journal 8(2): E236-E238

Martin, E.; Mayorga, C.; Rodriguez, R.; Torres, M.J.; Blanca, M. 2005: Drug hypersensitivity: insights into pathomechanisms. European Annals of Allergy and Clinical Immunology 37(6): 207-212

Forrester, M.B. 2006: Drug identification calls from law enforcement received by Texas poison control centers, 2002-2004. Journal of toxicology and environmental health. Part A 69(22): 2041-2049

Brown, D.M.; Pellecchia, M.; Ruoslahti, E. 2004: Drug identification through in vivo screening of chemical libraries. Chembiochem: a European Journal of Chemical Biology 5(6): 871-875

Jaramillo, J.E.; Anderson, H.G.; Jaramillo, J.P.; Nester, M.L.; Shum, S. 2004: Drug identification: a survey of poison control centers. Journal of Toxicology. Clinical Toxicology 42(4): 371-381

Discombe, G. 1953: Drug idiosyncrasy and drug sensitization. Practitioner 170(1018): 373-380

Mueller, X.M. 2004: Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Annals of Thoracic Surgery 77(1): 354-362

Mueller, X.M. 2004: Drug immunosuppression therapy for adult heart transplantation. Part 2: clinical applications and results. Annals of Thoracic Surgery 77(1): 363-371

Jukarainen, H.; Strömberg, C. 2004: Drug implants, technology serving delivery. Duodecim; Laaketieteellinen Aikakauskirja 120(16): 2008-2014

Thompson, C.A. 2004: Drug importation not the right answer, Nobel economist says. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 61(6): 546; 548

Thompson, C.A. 2004: Drug importation raises issues for pharmacists. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 61(4): 328; 333-334

Chi, B.; Serafin, D.; Robertson, W.O. 2003: Drug imprinting ('unit labeling')--an update and a plea!. Veterinary and Human Toxicology 45(1): 1-2

Cooter, R. 2004: Historical keywords: bioethics. Lancet 364(9447): 1749

Anonymous 2004: Drug in four countries meet U.S. standards. Aids Alert 19(7): 84

Mintz, S.R. 1962: Drug incompatibilities in anesthesia. Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society 114: 121-123

Rodig, F. 1957: Drug incompatibilities in doctor's prescriptions. Das Deutsche Gesundheitswesen 12(3): 86

Boughton, B. 2003: Drug increases lean tissue mass in patients with cancer. Lancet. Oncology 4(3): 135

Tornabuoni, C. 1952: New colorimetric reaction in the determination of formaldehyde, triformaldehyde, hexamethylenetetramine and hexamethylenetetramine anhydromethylencitrate. Bollettino Chimico Farmaceutico 91(3): 89-91

Andrén-Sandberg, A. 2003: Drug indoctrination or education? You are member of the county council's political committee. Lakartidningen 100(42): 3328-3332

Goriainov, V.; McEwan, J.K.; Oreffo, R.O.; Dunlop, D.G. 2018: Application of 3D-printed patient-specific skeletal implants augmented with autologous skeletal stem cells. Regenerative Medicine 13(3): 283-294

Ogawa, Y.; Yoshida, H. 2006: Drug induced androgen dysgenesis. Nihon Rinsho. Japanese Journal of Clinical Medicine Suppl 2: 317-320

Kharoubi, S. 2003: Drug induced anosmia with nifedipine. Presse Medicale 32(27): 1269-1272

Clauss, R.; Nel, W. 2006: Drug induced arousal from the permanent vegetative state. Neurorehabilitation 21(1): 23-28

Imes, R.K. 2005: Drug induced autoenucleation with resultant chiasmal damage. British Journal of Ophthalmology 89(6): 783

Ovsyshcher, I.E.; Barold, S.S. 2004: Drug induced bradycardia: to pace or not to pace?. Pacing and Clinical Electrophysiology: Pace 27(8): 1144-1147

Roseo, B.; Poggi Longostrevi, G. 1963: Drug induced changes of the body response to radiation injury. Inhibition of the CNS and endocrine stimulation. Immediate results. Radiobiologia Radioterapia e Fisica Medica 18: 72-77

Naito, Y.; Kuzuhara, S. 2004: Drug induced dementia--anti-parkinsonian drugs. Nihon Rinsho. Japanese Journal of Clinical Medicine 62 Suppl: 470-474

Kutter, D. 1959: Drug induced disorders of research on urobilinogen and urobilin in the urine. Bulletin de la Societe des Sciences Medicales du Grand-Duche de Luxembourg 96(2): 201-204

Macedo, G.; Sarmento, J.é A.; Lopes, S. 2006: Drug induced esophageal ulceration. Gastroenterologie Clinique et Biologique 30(2): 334-335

Kang, D.-Y.; Jin, S.-Y. 2006: Drug induced hepatitis mimicking alcoholic hepatitis. Korean Journal of Hepatology 12(4): 574-578

Kasemann, W. 1953: Drug induced labor in prolonged pregnancy. Archiv für Gynakologie 183: 601-604

Montagnac, R.; Reguiaï, Z.; Méhaut, S.; Bressieux, J.M.; Schillinger, F. 2003: Drug induced linear IgA bullous dermatosis. Nephrologie 24(6): 287-292

Contreras, J.; Poniachik, J.; Planzer, M.; Lazarte, R.úl.; Smok, G.; Oksenberg, D.; Madrid, A.M.ía.; Brahm, J. 2003: Drug induced liver disease: clinical and pathological patterns in 33 cases. Revista Medica de Chile 131(10): 1128-1134

Byrnes, V.; Afdhal, N.; Challies, T.; Greenstein, P.E. 2006: Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis. Annals of Hepatology 5(1): 56-59

Kudo, S. 2006: Drug induced lung injuries in Japanese population. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 95(6): 1058-1062

Weeda, L.W. 2006: Drug induced osteonecrosis of the jaws. Journal of the Tennessee Dental Association 86(2): 18-19

Singh, S. 2005: Drug induced pancreatitis might be a class effect of statin drugs. JOP: Journal of the pancreas 6(4): 380; author reply 380-1

Bruneau, J.-M.; Maillet, I.; Tagat, E.; Legrand, R.; Supatto, F.ço.; Fudali, C.; Caer, J.-P.L.; Labas, V.ér.; Lecaque, D.; Hodgson, J. 2003: Drug induced proteome changes in Candida albicans: comparison of the effect of beta(1,3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics 3(3): 325-336

Devi, D.Padmini.; Sushma, M.; Guido, S. 2004: Drug induced serious hepatic adverse reactions in a tertiary care centre: a five-year retrospective analysis. Indian Journal of Medical Sciences 58(5): 211-212

Li, C.-s.; Xu, H.-r. 2003: Drug induced suffering for the aged and rational usage on Chinese drugs. Zhongguo Zhong Xi Yi Jie he Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 23(9): 703-707

Cano Parra, J.; Díaz-Llopis, M. 2005: Drug induced uveitis. Archivos de la Sociedad Espanola de Oftalmologia 80(3): 137-149

Sundling, S. 1959: Drug industry & advertising methods. Svensk Farmaceutisk Tidskrift 63(18): 484-486

Annertz, Mårten. 2004: Drug industry and bribes. Lakartidningen 101(15-16): 1436

Flaten, O.; Korsvold, J. 2007: Drug industry and neglected diseases. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 127(3): 319

Waeber, B.; Burnier, M.; Pechère-Bertschi, A. 2005: Drug industry influence on hypertension treatment trials. Revue Medicale Suisse 1(32): 2067-2068

Fleck, F. 2004: Drug industry is not tackling threats to public health, says WHO. Bmj 329(7477): 1256

Melander, A. 2004: Drug industry is not to be subsidized by the society. Lakartidningen 101(7): 613; author reply 613

Meier, B. 2005: Drug industry plans release of more data about studies. New York Times on the Web 2005: C4

Burton, B. 2004: Drug industry to fight New Zealand's move to ban direct to consumer advertising. Bmj 328(7447): 1036

Burton, B. 2006: Drug industry told to disclose details of doctors' events. Bmj 333(7562): 278

Coombes, R. 2005: Drug industry's new code criticised for lacking teeth. Bmj 331(7527): 1225

Koren, B. 2005: Drug industry, the Medical Society and the others. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 125(15): 2055

Erickson, O.F. 1960: Drug influences on lacrimal lysozyme production. Stanford Medical Bulletin 18: 34-39

Christensen, K.L. 2005: Drug information about lercanidipine. a new dihydropyridine calcium antagonist for the treatment of arterial hypertension. Ugeskrift for Laeger 167(2): 153-155

Hach, I.; Meusel, D.; Maywald, U.; Kirch, W. 2005: Drug information centers-instruments for health care research?. Medizinische Klinik 100(7): 396-400

Thompson, C.A. 2005: Drug information confuses pregnant patients' health care providers. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 62(13): 1342; 1344, 1346

Wang, F.; Troutman, W.G.; Seo, T.; Peak, A.; Rosenberg, J.M. 2006: Drug information education in doctor of pharmacy programs. American Journal of Pharmaceutical Education 70(3): 51

Ball, D.E.; Tagwireyi, D.; Maponga, C.C. 2007: Drug information in Zimbabwe: 1990-1999. Pharmacy World and Science: Pws 29(3): 131-136

Zwaenepoel, L.; Laekeman, G. 2003: Drug information in psychiatric hospitals in Flanders: a study of patient-oriented leaflets. Pharmacy World and Science: Pws 25(6): 247-250

Foged, A.; Bjerrum, L. 2003: Drug information leaflets confuse patients. Ugeskrift for Laeger 165(36): 3433; Author Reply 3433-4

Beorlegui Martincorena, B.; Ortega Eslava, A.; Aquerreta González, I.; Aldaz Pastor, A.; Lacasa Arregui, C.; Idoate García, A.; Conchillo Armendáriz, A.; Giráldez Deiró, J.; Morales De Alava, I.; Yuste Ara, J.R.; García González, N. 2003: Drug information made available to the population via Internet from a Pharmacy Department. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 27(6): 353-359

Juárez Giménez, J.C.; Mendarte Barrenechea, L.; Gil Luján, G.; Sala Piñol, F.; Lalueza Broto, P.; Girona Brumós, L.; Monterde Junyent, J. 2006: Drug information management through the intranet of a hospital center. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 30(1): 49-52

Anderson, I.M. 2004: Drug information not regulation is needed. Journal of Psychopharmacology 18(1): 14-5; Author Reply 18-9

Ball, D.E.; Al-Othman, F. 2007: Drug information resources at private community pharmacies in Kuwait. Medical Principles and Practice: International Journal of the Kuwait University Health Science Centre 16(2): 107-109

Murphy, A.L.; Fleming, M.; Martin-Misener, R.; Sketris, I.S.; MacCara, M.; Gass, D. 2006: Drug information resources used by nurse practitioners and collaborating physicians at the point of care in Nova Scotia, Canada: a survey and review of the literature. Bmc Nursing 5: 5

Sleath, B.; Wurst, K.; Lowery, T. 2003: Drug information sources and antidepressant adherence. Community Mental Health Journal 39(4): 359-368

Brand, K.Alicia.; Kraus, M.L. 2006: Drug information specialists. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 63(8): 712-714

Liu, D.; Fu, J.; Fan, H.; Li, D.; Dong, E.; Xiao, X.; Wang, L.; Guo, Z. 2018: Application of 3D-printed PEEK scapula prosthesis in the treatment of scapular benign fibrous histiocytoma: A case report. Journal of Bone Oncology 12: 78-82

Manso Rodríguez, G.; Hidalgo Balsera, Aín. 2005: Drug information: summary of product characteristics. Medicina Clinica 125(5): 198

Garattini, S. 1957: Drug inhibitors of coenzyme a and intervening in the metabolism of cholesterol. Therapie 12(1): 86-93

Marder, S.R. 2006: Drug initiatives to improve cognitive function. Journal of Clinical Psychiatry 67(Suppl 9): 31-35; Discussion: 36-42

Roy, E.; Haley, N.; Leclerc, P.; Cédras, L.; Blais, L.; Boivin, J.-F.ço. 2003: Drug injection among street youths in Montreal: predictors of initiation. Journal of Urban Health: Bulletin of the new York Academy of Medicine 80(1): 92-105

Lankenau, S.E.; Clatts, M.C. 2004: Drug injection practices among high-risk youths: the first shot of ketamine. Journal of Urban Health: Bulletin of the new York Academy of Medicine 81(2): 232-248

Coscas, G. 1959: Carbon monoxide poisoning. Gazette Medicale de France 66(1): 55-56 Passim

Kaerber, G. 1964: Drug injuries: Their registration and documentation from the viewpoint of the "Bundesgesundheitsamt" (federal health office). Methods of Information in Medicine 3(3-4): 127-131

Khapra, A.P.; Rose, S. 2006: Drug injury in the upper gastrointestinal tract: effects of alendronate. Gastrointestinal Endoscopy Clinics of North America 16(1): 99-110

Go, M.F. 2006: Drug injury in the upper gastrointestinal tract: nonsteroidal anti-inflammatory drugs. Gastrointestinal Endoscopy Clinics of North America 16(1): 83-97

Steele, M.; Weiss, M.; Swanson, J.; Wang, J.; Prinzo, R.S.; Binder, C.E. 2006: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Canadian Journal of Clinical Pharmacology 13(1): E50-E62

Young, D. 2007: Drug innovation on the decline. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 64(3): 228; 231

Gupta, K.; Cline, R.R.; Schondelmeyer, S.W. 2006: Drug insurance instability and its correlates: results from the 2000 Medical Expenditure Panel Survey. Research in Social and Administrative Pharmacy: Rsap 2(2): 232-253

Guo, H-Chang.; Wang, Y.; Dai, J.; Ren, C-Wei.; Li, J-Hua.; Lai, Y-Qiang. 2018: Application of 3D printing in the surgical planning of hypertrophic obstructive cardiomyopathy and physician-patient communication: a preliminary study. Journal of Thoracic Disease 10(2): 867-873

Checa, M.A.; Peiró, R.; Pascual, J.; Carreras, Rón. 2005: Drug intake behaviour of immigrants during pregnancy. European Journal of Obstetrics Gynecology and Reproductive Biology 121(1): 38-45

Francke, D.E. 2006: Drug intelligence--objectives and scope. Annals of PharmacoTherapy 40(1): 114

Kuypers, D.R.; Claes, K.; Evenepoel, P.; Maes, B.; Vandecasteele, S.; Vanrenterghem, Y.; Van Damme, B.; Desmet, K. 2005: Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. Transplantation 79(6): 737

Sarino, L.V.; Dang, K.H.; Dianat, N.; Djihanian, H.; Natanian, N.; Hudmon, K.S.; Ambrose, P.J. 2007: Drug interaction between oral contraceptives and St. John's Wort: appropriateness of advice received from community pharmacists and health food store clerks. Journal of the American Pharmacists Association: Japha 47(1): 42-47

Perrin, Y.; Buclin, T.; Biollaz, J. 2004: Drug interaction computer programs: which choice?. Praxis 93(23): 991-996

Anderson, R.J.; Divers, C.; von Hennigs, I. 2005: Drug interaction exposure in chronic atrial fibrillation patients maintained on warfarin. Journal of Thrombosis and Thrombolysis 19(2): 123-124

Gravenstein, J.S.; Andersen, T.W. 1961: Drug interaction in anesthesia. Southern Medical Journal 54: 278-280

Hansten, P.D. 2003: Drug interaction management. Pharmacy World and Science: Pws 25(3): 94-97

Niwa, T.; Honda, S.; Shirakawa, K.; Imamura, Y.; Osaki, S.; Takagi, A. 2006: Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 128(2): 93-103

Alscher, D.M.; Klotz, U. 2003: Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transplant International: Official Journal of the European Society for Organ Transplantation 16(7): 543-544

Momo, K.; Doki, K.; Hosono, H.; Homma, M.; Kohda, Y. 2004: Drug interaction of tizanidine and fluvoxamine. Clinical Pharmacology and Therapeutics 76(5): 509-510

Yoshikawa, S.; Satou, K.; Konagaya, A. 2004: Drug interaction ontology (DIO) for inferences of possible drug-drug interactions. Studies in Health Technology and Informatics 107(Part 1): 454-458

Alayeto, M.E. 2005: Drug interaction screens are pharmacists' responsibility. Journal of the American Pharmacists Association: Japha 45(2): 116; 119

Hartshorn, E.A. 2006: Drug interaction: 1. General considerations. Annals of PharmacoTherapy 40(1): 116-118

Highleyman, L. 2005: Drug interactions and anti-HIV therapy. Beta: Bulletin of Experimental Treatments for Aids: a Publication of the San Francisco Aids Foundation 17(4): 20-29

Spigset, O. 2005: Drug interactions and databases. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 125(3): 330

Elliott, W.J. 2006: Drug interactions and drugs that affect blood pressure. Journal of Clinical Hypertension 8(10): 731-737

Zhao, F.; Zhao, G.; Weijie, F.; Chen, L. 2018: Application of 3D printing technology in RGPCL simulation fitting. Medical Hypotheses 113: 74-76

Kroon, L.A. 2006: Drug interactions and smoking: raising awareness for acute and critical care providers. Critical Care Nursing Clinics of North America 18(1): 53-62 Xii

Faragon, J.J.; Piliero, P.J. 2003: Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. Aids Reader 13(9): 433

Regal, R.E.; Ong Vue, C. 2004: Drug interactions between antibiotics and select maintenance medications: seeing more clearly through the narrow therapeutic window of opportunity. Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists 19(12): 1119-1128

Filler, G. 2004: Drug interactions between mycophenolate and cyclosporine. Pediatric Transplantation 8(3): 201-204

McCance-Katz, E.F.; Rainey, P.M.; Smith, P.; Morse, G.D.; Friedland, G.; Boyarsky, B.; Gourevitch, M.; Jatlow, P. 2006: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. American Journal on Addictions 15(1): 23-34

McCance-Katz, E.F.; Rainey, P.M.; Smith, P.; Morse, G.; Friedland, G.; Gourevitch, M.; Jatlow, P. 2004: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. American Journal on Addictions 13(2): 163-180

Neuman, M.G.; Monteiro, M.; Rehm, Jürgen. 2006: Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Substance use and Misuse 41(10-12): 1395-1463

An, J.; Sun, Y.-P.; Adams, J.; Fisher, M.; Belldegrun, A.; Rettig, M.B. 2003: Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9(12): 4537-4545

Ogu, C.C.; Maxa, J.L. 2000: Drug interactions due to cytochrome P450. Proceedings 13(4): 421-423

Shakeri-Nejad, K.; Stahlmann, R. 2006: Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opinion on PharmacoTherapy 7(6): 639-651

Barré, E.; Bisseux, L.; Chiadmi, F.; Toledano, A.; Cisternino, S.; Schlatter, J.; Champault, G.; Ratiney, R.; Fontan, J.E. 2005: Drug interactions in an elderly population. Prospective assessment of their frequency and seriousness among 56 patients. Presse Medicale 34(12): 837-841

Nielsen, E.W.; Dybwik, K. 2004: Drug interactions in an intensive care unit. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 124(22): 2907-2908

Egan, L.J. 2004: Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 2(9): 725-730

Beijnen, J.H.; Schellens, J.H.M. 2004: Drug interactions in oncology. Lancet. Oncology 5(8): 489-496

Robertson, S.M.; Penzak, S.R.; Pau, A.K. 2005: Drug interactions in the management of HIV infection. Expert Opinion on PharmacoTherapy 6(2): 233-253

López Vázquez, P.; Rodríguez Moreno, C.; Durán Parrondo, C.; Tato Herrero, F.; Rodríguez López, I.; Lado Lado, F.L. 2005: Drug interactions in the prescription of medical patients at hospital discharge. Anales de Medicina Interna 22(2): 69-75

Shapiro, L.; Knowles, S.; Shear, N. 2003: Drug interactions of clinical significance for the dermatologist: recognition and avoidance. American Journal of Clinical Dermatology 4(9): 623-639

Dunner, D.L. 2003: Drug interactions of lithium and other antimanic/mood-stabilizing medications. Journal of Clinical Psychiatry 64(Suppl 5): 38-43

Sumner, M.E.; Albers, S.; Schmidt, K.G.; Laws, H.J.ür.; Läer, S. 2006: Drug interactions of tacrolimus. Medizinische Monatsschrift für Pharmazeuten 29(4): 139-141

Haen, E. 2004: Drug interactions with H1 antihistamines. Pharmazie in Unserer Zeit 33(2): 106-107

Böhler, S.; Pittrow, D.; Bramlage, P.; Kirch, W. 2005: Drug interactions with angiotensin receptor blockers. Expert Opinion on Drug Safety 4(1): 7-18

Becquemont, L. 2003: Drug interactions with antilipemics. Therapie 58(1): 85-90

Catanzaro, L.M.; Slish, J.C.; DiCenzo, R.; Morse, G.D. 2004: Drug interactions with antiretrovirals. Current Hiv/Aids Reports 1(2): 89-96

Anonymous 2004: Drug interactions with grapefruit juice. Medical letter on drugs and therapeutics 46(1173): 2-4

Guillebaud, J. 2005: Drug interactions with hormonal contraception. journal of family planning and reproductive health care 31(4): 335-6; author reply 336

Toes, M.J.; Jones, A.L.; Prescott, L. 2005: Drug interactions with paracetamol. American Journal of Therapeutics 12(1): 56-66

Sibert, L.; Kuhn, J.M.; Rossi, D.; Tostain, J. 2004: Drug interactions with the androgen balance of adult men. Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 14(5): 679-683

Litt, J.Z. 2004: Drug interactions--fact or fiction?. Disease-A-Month: Dm 50(7): 422-431

Aronson, J.K. 2004: Drug interactions-information, education, and the British National Formulary. British Journal of Clinical Pharmacology 57(4): 371-372

Anonymous 2006: Drug interactions. Amprenavir with low-dose ritonavir. TreatmentUpdate 18(3): 9-10

Feman, S.S. 2006: Thalassemia. Annals of Ophthalmology 38(1): 8-9

Anonymous 2006: Drug interactions. Brecanavir--a new protease inhibitor. TreatmentUpdate 18(3): 6-7

Friedlaender, M.H. 2006: Phakic intraocular lens for myopia. Annals of Ophthalmology 38(1): 9-11

Anonymous 2006: Drug interactions. Coming soon--a new formulation of saquinavir (Invirase). TreatmentUpdate 18(3): 9

Anonymous 2006: Drug interactions. Gilead's integrase inhibitor. TreatmentUpdate 18(3): 5-6

Anonymous 2006: Drug interactions. Interactions with TMC114 and TMC125. TreatmentUpdate 18(3): 8-9

Anonymous 2006: Drug interactions. Introduction: careful combinations. TreatmentUpdate 18(3): 1-2

Anonymous 2006: Drug interactions. Is atazanavir best when boosted with ritonavir?. TreatmentUpdate 18(3): 3

Anonymous 2006: Drug interactions. Kaletra and atazanavir. TreatmentUpdate 18(3): 7-8

Friedlaender, M.H. 2006: Blepharitis, allergy, and dry eye: lumpers and splitters. Annals of Ophthalmology 38(1): 4-5

Klotz, U.; Beil, W.; Gleiter, C.; Drewelow, B.; Garbe, E.; Gillessen, A.; Mutschler, E. 2003: Drug interactions. Mechanisms and clinical relevance. Der Internist 44(11): 1444-1449

Burton, A. 2006: Speeding up cancer-drug development. European Journal of Cancer 42(17): 2858

Anonymous 2005: Drug interactions. Rosiglitazone and anti-HIV agents. TreatmentUpdate 17(4): 8

Anonymous 2006: Drug interactions. Super pills-the treatments of the future?. TreatmentUpdate 18(3): 2-3

Anonymous 2006: Drug interactions. Unexpected interaction between T-20 and some protease inhibitors. TreatmentUpdate 18(3): 5

Byrne, B.Ellen. 2003: Drug interactions: a review and update. Alpha Omegan 96(4): 10-17

Brucker, M.C. 2005: Drug interactions: beyond polypharmacy and P-450... Awhonn Lifelines 9(5): 408-410

Nassar, A.-E.F.; Talaat, R.E.; Tokuno, H. 2007: Drug interactions: concerns and current approaches. Idrugs: the Investigational Drugs Journal 10(1): 47-52

Scheen, A.J. 2006: Drug interactions: from theory to practice. Revue Medicale de Liege 61(5-6): 471-482

Rumel, D.; Nishioka, S.ér.d.A.; Santos, A.él.A.M.ça.d. 2006: Drug interchangeability: clinical approach and consumer's point of view. Revista de Saude Publica 40(5): 921-927

Delacour, H.; Dami, A.; Gidenne, S.; Vigezzi, J.-F.; Le Rest, N.; Ramirez, J. 2003: Drug interference with the determination of urinary proteins with pyrocatechol violet Upro Vitros slides. Annales de Biologie Clinique 61(6): 709-712

Ozturk, O.; Saridogan, E.; Jauniaux, E. 2004: Drug intervention in early pregnancy after assisted reproductive technology. Reproductive Biomedicine Online 9(4): 452-465

Ritter, C.; Andrades, M.; Reinke, A.; Moreira, Jé.Cláudio.F.; Dal-Pizzol, F. 2004: Drug intervention trials in sepsis. Lancet 364(9433): 498

Niedoszytko, M.; Chelminska, M.; Buss, T.; Roik, E.; Jassem, E. 2006: Drug intolerance in patients with idiopathic environmental intolerance syndrome. International Journal of Clinical Practice 60(10): 1327-1329

Jancsin, J. 1952: Drug intoxication in combined PAS-streptomycin therapy. Beitrage Zur Klinik der Tuberkulose und Spezifischen Tuberkulose-Forschung 107(2): 147-151

Mundle, M.; Biswas, R.; Sinha, S.; Bhadra, U. 2002: Drug inventory management in Medical College Hospital, Kolkata. Indian journal of public health 46(1): 31-33

Theodore, F.H. 1963: Drug irritations from miotics. Eye Ear Nose and Throat Monthly 42: 74 Concl

Tiwary, D. 2003: Drug labeling: FDA requires new label for antibiotics to prevent overuse. Journal of Law Medicine and Ethics: a Journal of the American Society of Law Medicine and Ethics 31(3): 458-460

Wang, Y.; Wang, C.-z. 2003: Dendritic cells and bronchial asthma. Zhonghua Jie he He Hu Xi Za Zhi 26(12): 790-792

Anonymous 2004: Drug labeling; sodium labeling for over-the-counter drugs. Final rule. Federal Register 69(228): 69278-69280

Oest, O. 1962: Drug labelling--essential and up-to-date. Shall labels be "sold"? Methods of labelling. Formula signatures with heating arrangement. Svensk Farmaceutisk Tidskrift 66: 461-467

Baumgarten, R.K. 2006: Drug labels should evolve with medical knowledge. Anesthesiology 104(5): 1107

Harper, N.J. 1959: Drug latentiation. Journal of Medicinal and Pharmaceutical Chemistry 1: 467-500

Bateman, C. 2004: Drug laws--state to comply... but later. South African Medical Journal 94(8): 605

Benko, L.B. 2006: Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation. Modern Healthcare 36(15): 16

Ruckpaul, K. 1958: Drug legislation in Germany. Das Deutsche Gesundheitswesen 13(41): 1295-1297

Regenthal, R.; Krueger, M.; Koeppel, C.; Preiss, R. 1999: Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. Journal of Clinical Monitoring and Computing 15(7-8): 529-544

Huhle, G. 1960: Drug list for pharmacies. Pharmazeutische Praxis 7: 155

Anonymous 2004: Drug maker to pay \$430 million in fines, civil damages. Fda Consumer 38(4): 36-37

Moynihan, R. 2004: Drug maker urges group to lobby FDA on testosterone for women. Bmj 329(7477): 1255

Harris, G.; Pear, R. 2006: Drug maker's efforts to compete in lucrative insulin market are under scrutiny. New York Times on the Web 2006: A14

Strom, S.; Fleischer-Black, M. 2003: Drug maker's vow to donate cancer medicine falls short. New York Times on the Web 2003: A1 C7

Harris, G. 2005: Drug makers are still giving gifts to doctors, F.D.A. officials tell senators. New York Times on the Web 2005: A15

Saul, S. 2006: Drug makers pay for lunch as they pitch. New York Times on the Web 2006: A1 C7

Meune, C. 2006: Drug management for coronary artery disease in the elderly. Archives des Maladies du Coeur et des Vaisseaux 99(Special Issue 4): 35-39

Blackwell, A.Elizabeth.; Beck, J.M. 2003: Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory. Food and Drug Law Journal 58(3): 439-462

Junod, V. 2004: Drug marketing exclusivity under United States and European Union law. Food and Drug Law Journal 59(4): 479-518

Charatan, F. 2004: Drug marketing practices come under scrutiny. Bmj 329(7456): 10

Anonymous 2006: Drug may slow brain shrinkage in pre-Alzheimer's disease. Mayo Clinic Health Letter 24(12): 4

Anonymous 2005: Drug may temporarily slow progression of mild cognitive impairment. Mayo Clinic Women's Healthsource 9(8): 3

Wynne, H. 2005: Drug metabolism and ageing. Journal of the British Menopause Society 11(2): 51-56

Roberts, S.A. 2003: Drug metabolism and pharmacokinetics in drug discovery. Current Opinion in Drug Discovery and Development 6(1): 66-80

Alavijeh, M.S.; Chishty, M.; Qaiser, M.Zeeshan.; Palmer, A.M. 2005: Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neurorx: the Journal of the American Society for Experimental Neurotherapeutics 2(4): 554-571

Bjarnason, N.H. 2005: Drug metabolism and variability. New England Journal of Medicine 353(9): 955

Wilkinson, G.R. 2005: Drug metabolism and variability among patients in drug response. New England Journal of Medicine 352(21): 2211-2221

Kreutzkamp, B. 2006: Drug metabolism by the cytochrome p-450 enzyme. Variability of polymorphisms and exogenous carriers. Medizinische Monatsschrift für Pharmazeuten 29(2): 48-50

Suga, T. 2003: Drug metabolism in peroxisomes: involvement of peroxisomal beta-oxidation system in the oxidative chain-shortening of xenobiotic acyl compounds. Drug Metabolism and Pharmacokinetics 18(3): 155-162

Weikel, J.H. 1956: Drug metabolism; an index of toxicity. International Record of Medicine and General Practice Clinics 169(1): 45-47

Juchau, M.R.; Niswander, K.R.; Yaffe, S.J. 1968: Drug metabolizing systems in homogenates of human immature placentas. American Journal of Obstetrics and Gynecology 100(3): 348-356

Kuczkowski, K.M. 2006: Drug mislabeling errors [corrected] in (obstetric) [corrected] anaesthesia. Acta Anaesthesiologica Belgica 57(1): 57

Sinclair, K.; Collins, D.; Potokar, J. 2003: Drug misuse by patients in an inner-city hospital. Nursing Standard: 17(41): 33-37

Kuczkowski, K.M. 2004: Drug misuse in pregnancy. British Journal of Psychiatry: the Journal of Mental Science 184: 182

Whelan, K.; Jones, A.; Dargan, P. 2003: Drug misuse should always be considered in young people with impaired consciousness. Bmj 326(7385): 396

Bhala, B. 2003: Drug mix-up during resuscitation. Anaesthesia 58(9): 935

Forkner, C.E. 1958: Drug mixtures. New England Journal of Medicine 259(9): 438-439

Fuchs, H.R.; Giertz, H. 1960: Drug mixtures with analgesic effect. Arzneimittel-Forschung 10: 526-530

Huntzinger, J.A.; Witoslawski, J.J.; Hanson, H.M. 1959: Drug modification of runway behavior of mice influenced by aversive stimulus. Journal of the American Pharmaceutical Association. American Pharmaceutical Association 48: 605-606

Iskandar, S.B.; Byrd, R.P. 2006: Drug modified arrhythmia: what's your diagnosis?. Tennessee Medicine: Journal of the Tennessee Medical Association 99(9): 37-38

Souillé, N.; Palazzolo, J.ér.ôm. 2005: Drug monitoring and nursing practice. SOINS. Psychiatrie 237: 41-44

Juenke, J.; Brown, P.I.; Urry, F.M.; McMillin, G.A. 2006: Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. Journal of Analytical Toxicology 30(1): 27-30

Juenke, J.M.; Brown, P.I.; Urry, F.M.; McMillin, G.A. 2006: Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. Journal of Chromatographic Science 44(1): 45-48

Falkensammer, B.; Fasser, W.; Scherer, K.; Zemann, A.; Parson, W.; Ulmer, H.; Dierich, M.P.; Stoiber, H. 2005: Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. International Journal of Immunopathology and Pharmacology 18(1): 145-154

Segura, Aída.E.del.V.; Mutal, Víctor.; Lizzio, S.; Montrull, H.L. 2005: Drug monitoring in hospitals of Cordoba City (Argentina). 2-year-experience of the Pharmacological Department as a peripheric effect of ANMAT. Revista de la Facultad de Ciencias Medicas 62(1): 15-20

Langmann, P.; Schirmer, D.; Zilly, M.; Klinker, H. 2004: Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 10(5): Pi65-Pi69

Filik, R.; Purdy, K.; Gale, A.; Gerrett, D. 2004: Drug name confusion: evaluating the effectiveness of capital ("Tall Man") letters using eye movement data. Social Science and Medicine 59(12): 2597-2601

Rados, C. 2005: Drug name confusion: preventing medication errors. Fda Consumer 39(4): 35-37

Woods, W.E. 1961: Drug name integrity. Hospital Management 91: 18-21

Matteucci, M.E.; Hotze, M.A.; Johnston, K.P.; Williams, R.O. 2006: Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir: the Acs Journal of Surfaces and Colloids 22(21): 8951-8959

Gaig, P.; García-Ortega, P.; Baltasar, M.; Bartra, J. 2006: Drug neosensitization during anticonvulsant hypersensitivity syndrome. Journal of Investigational Allergology and Clinical Immunology 16(5): 321-326

Autret-Leca, E. 2005: Drug news. Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie 12(7): 1148-1152

Vallano Ferraz, A.; Llop Rius, R.; Bosch Ferrer, M.; Danés Carreras, I. 2005: Drug notices in the health supplement of Spanish newspapers. Medicina Clinica 124(19): 754-755

Scheen, A.J. 2004: Drug of the month. Rosuvastatin (Crestor). Revue Medicale de Liege 59(1): 56-59

Piérard, G.E.; Arrese, J.E.; Quatresooz, P.; Piérard-Franchimont, C. 2003: Drug of the month. Voriconazole (Vfend). Revue Medicale de Liege 58(5): 351-355

Holly, N. 1962: Drug on the market. Medical World 96: 141-146

Tice, L.F. 1960: Drug or beverage?. American Journal of Pharmacy and the Sciences Supporting Public Health 132: 84-85

Cooper, D.J. 2002: Drug overdosage: a disorder that is now rarely managed in the tertiary hospital intensive care unit?. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine 4(3): 163-164

Miyake, Y. 2006: Drug overdose patients: do all of them need hospitalization?. Chudoku Kenkyu: Chudoku Kenkyukai Jun Kikanshi 19(2): 125-131

Galea, S.; Coffin, P.O. 2003: Drug overdose: new insights, innovative surveillance, and promising interventions. Journal of Urban Health: Bulletin of the new York Academy of Medicine 80(2): 186-188

Mitka, M. 2006: Drug package inserts get mixed reception. JAMA 295(10): 1110-1111

Lemonick, M.D. 2005: Mother nature's DNA. Time 165(25): 56-57

Kalk, A.; König, J.ür.; van Wijnen, A.; Wiegandt, A. 2003: Drug packaging: what can TB learn from leprosy control?. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 7(12): 1211

Trébucq, A. 2003: Drug packaging: would 'blister packs' improve compliance and is 'one-box, one patient' of interest for TB control programmes?. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 7(12): 1211-1212

Alloussi, S. 2005: Drug patch tips and tricks for general practice. Krankenpflege Journal 43(7-10): 186

Anonymous 2003: Drug patent. Court rejects Glaxo's motion to dismiss AZT patent lawsuit. Aids Policy and Law 18(15): 7

Ohana, P.; Tardieu, S.; Blin, O.; Tassy, S.éb.; Sambuc, R. 2004: Drug patents and other ways to protect pharmaceutical research. Therapie 59(2): 253-257

Love, J. 2004: Drug patents in poor countries. Health Affairs 23(5): 279; Author Reply 281

McLeod, H.L. 2004: Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics 5(2): 139-141

Manford, F.; Tronde, A.; Jeppsson, A.-B.; Patel, N.; Johansson, F.; Forbes, B. 2005: Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 26(5): 414-420

Suh, D.-C.; Thomas, S.K.; Valiyeva, E.; Arcona, S.; Vo, L. 2005: Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs and Aging 22(8): 695-707

Mauskopf, J.A.; Paramore, C.; Lee, W.C.; Snyder, E.H. 2005: Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. Journal of Managed Care Pharmacy: Jmcp 11(3): 231-251

Zuckerman, A.; Zuckerman, L. 2006: Drug plans. Compete for patients. Provider 32(1): 20

Civitareale, E. 1962: Drug plasters. on the use of water in auto-adhesive mixtures. Bollettino Chimico Farmaceutico 101: 867-870

Velásquez, G.án. 2003: Drug plundering. Assistenza Infermieristica e Ricerca: Air 22(3): 182-184

Rivas, P.; Polo, J.; de Górgolas, M.; Fernández-Guerrero, M.L. 2003: Drug points: Fatal lactic acidosis associated with tenofovir. Bmj 327(7417): 711

Gorceix, A. 1963: Drug poisoning by hypnotics and neuroleptics. La Revue du Praticien 13: 1275-1282

Kaszas, T.; Papp, G. 1960: Drug poisoning in childhood. Orvosi Hetilap 101: 1261-1264

McCambridge, J. 2004: Drug policy and the public good?. Addiction 99(3): 388

Marlowe, D.B.; DeMatteo, D.S. 2003: Drug policy by analogy: well, it's like this.. Psychiatric Services 54(11): 1455-1456

Duckett, S.J. 2004: Drug policy down under: Australia's pharmaceutical benefits scheme. Health Care Financing Review 25(3): 55-67

Parry, C.D.H.; Myers, B.; Plüddemann, A. 2004: Drug policy for methamphetamine use urgently needed. South African Medical Journal 94(12): 964-965

Kerr, T.; O'Briain, W. 2002: Drug policy in Canada--the way forward. Canadian Hiv/Aids Policy and Law Review 7(1): 1; 27-32

Room, R. 1991: Drug policy reform in historical perspective: movements and mechanisms. Drug and Alcohol Review 10(1): 37-43

Gray, J. 2002: Drug policy: an oxymoron?. Healthcarepapers 3(1): 56-62; Discussion: 87-94

Laupacis, A.; Anderson, G.; O'Brien, B. 2002: Drug policy: making effective drugs available without bankrupting the healthcare system. Healthcarepapers 3(1): 12-30

Luger, M.; Batey, R. 1993: Drug policy: must we choose between harm minimization and abstinence?. Drug and Alcohol Review 12(1): 3-5

McFarlance, A. 2002: Drug policy: the challenge is to overcome fragmentation. Healthcarepapers 3(1): 38-42: Discussion: 87-94

Băicuş, C.; Chivu, R. 2004: Drug politics--economic view-point of a practitioner. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 108(3): 674-678

Matsumoto, T.; Yamaguchi, A.; Asami, T.; Kamijo, A.; Iseki, E.; Hirayasu, Y.; Wada, K. 2005: Drug preferences in illicit drug abusers with a childhood tendency of attention deficit/hyperactivity disorder: a study using the Wender Utah Rating Scale in a Japanese prison. Psychiatry and Clinical Neurosciences 59(3): 311-318

Warnke, A.é; Blume, H. 2005: Drug preparations of calcium channel blockers. Pharmazie in Unserer Zeit 34(5): 400-410

Breitkreutz, J.ör. 2005: Drug preparations of proton pump inhibitors. Pharmazie in Unserer Zeit 34(3): 216-223

Wunder, S.; Brune, K. 2004: Drug prescribing in practitioner networks--improved treatment at no extra cost?. MMW Fortschritte der Medizin 146(51-52): 43-44

Silwer, L.; Stålsby Lundborg, C. 2005: Drug prescribing in primary care related to patient age. European Journal of General Practice 11(1): 23-24; 28

Puel, J. 2003: Drug prescription after acute coronary syndrome. La Revue du Praticien 53(6): 635-639

Rodríguez Escolar, C.; Fidalgo García, L. 2007: Drug prescription for chronic obstructive pulmonary disease and asthma by primary care physicians in the Spanish autonomous community of Madrid, 1996-2002. Archivos de bronconeumologia 43(2): 73-80

Carmo, T.A.d.; Nitrini, S.M.O.O. 2004: Drug prescription for pregnant women: a pharmacoepidemiological study. Cadernos de Saude Publica 20(4): 1004-1013

Tomasi, R.; de Girolamo, G.; Santone, G.; Picardi, A.; Micciolo, R.; Semisa, D.; Fava, S. 2005: Drug prescription in Italian Residential Facilities. Epidemiologia e psichiatria sociale 14(2): 77-90

Bakker, M.K.; Jentink, J.; Vroom, F.; Van Den Berg, P.B.; De Walle, H.E.K.; De Jong-Van Den Berg, L.T.W. 2006: Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. Bjog: An International Journal of Obstetrics and Gynaecology 113(5): 559-568

Nkogho Mengue, P.-G.; Grégoire, J.-P.; Moisan, J. 2005: Drug prescription practices in public medical centres in Gabon. Sante 15(4): 229-234

Durant, R.; Boulanger-Morel, M.; Ferry, J.; Blain, A.; Blain, H.; Jeandel, C. 2003: Drug prescriptions for the elderly. Results of a survey on 8,809 prescriptions obtained by coding in the North-East area of France. Presse Medicale 32(14): 630-637

Flowers, J. 2003: Drug prescriptions online--a growing business ... a growing concern. Nephrology News and Issues 17(3): 18-19

Naisbitt, D.John.; Pirmohamed, M.; Park, B.Kevin. 2005: Drug presentation to T cells. Journal of Allergy and Clinical Immunology 115(4): 876

Fischer, Tás. 2004: Drug prevention and preventive management of age related macular degeneration by positive modification of vascular endothelial dysfunction. Klinische Monatsblatter für Augenheilkunde 221(12): 1062

Bronzini, A.; Scotti, G. 1962: Drug prevention of pulmonary complications in aged patients with acute cerebrovascular diseases. Giornale di Gerontologia 10: 1147-1160

Felder, S. 2004: Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?. European Journal of Health Economics: Hepac: Health Economics in Prevention and Care 5(4): 324-329

Henry, D.A.; Hill, S.R.; Harris, A. 2005: Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA 294(20): 2630-2632

Fleck, F. 2003: Drug prices may be too high despite WTO deal. Bulletin of the World Health Organization 81(10): 774-775

Stjerna, M. 1950: Drug prices set by the official list in Sweden. Svensk Farmaceutisk Tidskrift 54(35): 735-736

Teunissen, H.P. 1962: Drug prices,public opinion, legal measures. Pharmaceutisch Weekblad 97: 425-432

Sharma, S.; Bakal, J.; Sharma, S.M.; Covert, D.; Shah, G.K. 2005: Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie 40(3): 369-377

Mark, S.M.; Pollack, M.M.; Griffin, A.G.; Gumpper, K.F.; Harding, J.P. 2006: Drug pricing model in a pediatric hospital. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 63(14): 1361-1366

Anonymous 2006: Drug pricing. AHF cautions company over new AIDS drug price. Aids Policy and Law 21(14): 1

Anonymous 2004: Drug pricing. AHF presses for indemnification over Norvir price increase. Aids Policy and Law 19(4): 2

Anonymous 2005: Drug pricing. AHF: Schwarzenegger bows to drug industry donations. Aids Policy and Law 20(19): 4

Anonymous 2005: Drug pricing. Dismissal is denied in Norvir price-boosting suit. Aids Policy and Law 20(21): 6

Anonymous 2004: Drug pricing. HIV/AIDS patients file federal antitrust suit against Abbott. Aids Policy and Law 19(9): 9

Anonymous 2005: Drug pricing. High price of Fuzeon, other recent drugs sets tough pricing precedent. Aids Policy and Law 20(14): 4

Bateman, C. 2003: Drug pricing: the end of the gravy train?. South African Medical Journal 93(11): 812-813

Kulsudjarit, K. 2004: Drug problem in southeast and southwest Asia. Annals of the new York Academy of Sciences 1025: 446-457

Elifson, K.W.; Klein, H.; Sterk, C.E. 2004: Drug problems and "at risk" women's involvement in HIV risk behaviors. Sozial- und Praventivmedizin 49(3): 198-207

Chen, Z.; Huang, K. 2007: Drug problems in China: recent trends, countermeasures, and challenges. International Journal of Offender Therapy and Comparative Criminology 51(1): 98-109

Buda, B.él. 2006: Drug problems, psychopathology in youth, factors of sociocultural background. Ideggyogyaszati Szemle 59(3-4): 132-134

Salhotra, V.S. 2003: Drug procurement and management. Journal of the Indian Medical Association 101(3): 175-176

DiFeo, T.J. 2003: Drug product development: a technical review of chemistry, manufacturing, and controls information for the support of pharmaceutical compound licensing activities. Drug Development and Industrial Pharmacy 29(9): 939-958

Reid, G.; Devaney, M.L.; Baldwin, S. 2006: Drug production, trafficking and trade in Asia and Pacific Island countries. Drug and Alcohol Review 25(6): 647-650

Anonymous 2004: Drug production. Production of antiviral ingredient slowed by dispute. Aids Policy and Law 19(4): 7

Brindley, M.J.; Longman, L.P.; Randall, C.; Field, E.A. 2003: Drug profile of adult patients attending five general dental practices in Merseyside: oral side-effects and potential interactions with dentally prescribed medication. Primary Dental Care: Journal of the Faculty of General Dental Practitioners 10(4): 113-118

Prichard, B.N. 1963: Drug profiles. the barbiturates. Medical World 99: 41-50

Grahame, R. 1960: Drug prophylaxis in migraine. a controlled clinical trial. British Medical Journal 2(5207): 1203-1207

Clyde, D.F. 1959: Drug prophylaxis of malaria amongst premunized schoolchildren. East African Medical Journal 36(1): 12-25

Kurniadhi, D.; Rahman, A.; Wijaya, L.K.; Sukmana, N. 2006: Drug provocation test in patient with antituberculosis drug allergy. Acta Medica Indonesiana 38(3): 150-153

Booij, J. 1957: Drug psychiatry. Nederlands Tijdschrift Voor Geneeskunde 101(40): 1869-1872

Becker, C. 2004: Drug pullout. Massive recall of Vioxx poses logistical problems. Modern Healthcare 34(42): 17

Sotoca-Momblona, J.é M.; Sisó-Almirall, A. 2006: Drug quality as a cause of drug related problems. Medicina Clinica 126(15): 599

Gupta, R.; Gupta, S. 2005: Drug rash due to levamisole. Indian Journal of Dermatology Venereology and Leprology 71(6): 428-429

van Leeuwen, J.F.; van der Hooft, C.S.; Vos, L.E.; Bekkenk, M.W.; van Zuuren, E.J.; Stricker, B.H.Ch. 2005: Drug rash with eosinophilia and systemic symptoms (DRESS) attributed to the oral skin-care supplement Imedeen. Nederlands Tijdschrift Voor Geneeskunde 149(24): 1353-1356

Passeron, T.; Ndir, M.Cissé.; Aubron, Cécile.; Hovette, P. 2004: Drug rash with eosinophilia and systemic symptoms (DRESS) due to streptomycin. Acta Dermato-Venereologica 84(1): 92-93

Yun, S.J.; Lee, J.-B.; Kim, E.J.; Quan, G.; Kim, S.-J.; Won, Y.-H.; Lee, S.-C. 2006: Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepine: formation of circulating auto-antibody against 190-kDa antigen. Acta Dermato-Venereologica 86(3): 241-244

Wolf, R.; Matz, H.; Marcos, B.; Orion, E. 2005: Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification. Clinics in Dermatology 23(3): 311-314

Friend, D.G. 1962: Drug reaction committees in hospitals. JAMA 181: 111-113

Glover, N.; Marcus, P.S. 1958: Drug reaction times during surgery and anesthesia. Southern Medical Journal 51(4): 478-481

Le Nouail, P.; Viseux, V.; Chaby, G.; Billet, A.; Denoeux, J.P.; Lok, C. 2006: Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy. Annales de Dermatologie et de Venereologie 133(8-9 Pt 1: 686-688

Anonymous 2004: Drug reaction. Rev. Jackson calls study 'crime against humanity'. Aids Policy and Law 20(1): 1

Gutman, A.B. 1957: Drug reactions characterized by cholestasis associated with intrahepatic biliary tract obstruction. American Journal of Medicine 23(6): 841-845

Motulsky, A.G. 1957: Drug reactions enzymes, and biochemical genetics. Journal of the American Medical Association 165(7): 835-837

Bickel, G. 1957: Drug reactions in medical practice. Revue Medicale de la Suisse Romande 77(7): 417-435

Lim, G. 1961: Drug reactions in the treatment of tuberculosis. Medical Journal of Malaya 15: 157-159

Youman, J.D. 1953: Drug reactions of importance in daily practice. Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society 105(10): 380-385

Calnan, C.D. 1960: Drug reactions with griseofulvin. Transactions of the St. John's Hospital Dermatological Society 45: 54-58

Heijer, A.; Nilzen, A.; Skog, E. 1960: Drug reactions. An examination of a 5-year case series with special regard to evaluating the so-called thrombocytopenic index. Acta Dermato-Venereologica 40: 35-45

Lowance, M.I. 1960: Drug reactions: report of 150 cases. Southern Medical Journal 53: 850-852

Foubister, V. 2003: Drug reactivates genes to inhibit cancer. Drug Discovery Today 8(10): 430-431

Olsson, L.; Swaren, U. 1960: Drug rebates. Svensk Farmaceutisk Tidskrift 64: 185-205

Rodts, M.F. 2004: Drug recalls and notification of practitioners. Orthopedic Nursing 23(6): 353-354

Palm, A. 1958: Sensitivity of prescription scales. Svensk Farmaceutisk Tidskrift 62(9): 201-202

Pritzel, K. 1950: Drug registration and trade names. Das Deutsche Gesundheitswesen 5(29): 918-919

Zhen, L.H. 2003: Drug registration application in China. Journal of Pharmacy and Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences Societe Canadienne des Sciences Pharmaceutiques 6(2): 211-214

Bezold, C.; Peck, J. 2005: Drug regulation 2056. Food and Drug Law Journal 60(2): 127-136

Couzin, J. 2005: Drug regulation. Plan B: a collision of science and politics. Science 310(5745): 38-39

Mayor, S. 2005: Drug regulator criticised for error in reporting consultation results. Bmj 330(7505): 1410

Gibson, L. 2004: Drug regulators study global treaty to tackle counterfeit drugs. Bmj 328(7438): 486

Anonymous 2004: Drug regulatory developments. The European regulatory environment. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 21(1): 101-102

Young, D. 2005: Drug regulatory process is focused on safety, officials claim. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 62(17): 1754; 1756, 1758

Vuorenkoski, L.; Toiviainen, H.; Hemminki, E. 2003: Drug reimbursement in Finland-a case of explicit prioritizing in special categories. Health Policy 66(2): 169-177

Cretikos, M.A.; Parr, M.J.A. 2003: Drug related admissions to intensive care: the role of illicit drugs and self poisoning. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine 5(4): 253-257

Rajasekaran, D.; Chandrasekar, S.; Rajendran, M. 2006: Drug related crisis in myasthenia gravis. Journal of the Association of Physicians of India 54: 820-821

Khan, F.A.; Hoda, M.Q. 2005: Drug related critical incidents. Anaesthesia 60(1): 48-52

Seymour, A.; Black, M.; Simpson, K.; Oliver, J.S. 2000: Drug related deaths amongst Glasgow city hostel dwellers. Journal of Clinical Forensic Medicine 7(4): 183-187

Martín Conde, M.ía.T. 2005: Drug related problems. Medicina Clinica 124(7): 261-262

Paulino, E.I.; Bouvy, M.L.; Gastelurrutia, M.A.; Guerreiro, M.; Buurma, H. 2004: Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharmacy World and Science: Pws 26(6): 353-360

Arcavi, L.; Shahar, A. 2003: Drug related taste disturbances: emphasis on the elderly. Harefuah 142(6): 446-450; 485, 484

Liu, Z.-s.; Xie, L.-x.; Shi, W.-y.; Li, S.-w.; Cai, Q.; Bei, J.-z.; Wang, S.-g. 2004: Drug release and biocompatibility of cyclosporine a drug delivery system implanting into the anterior chamber. Chinese Journal of Ophthalmology 40(2): 108-112

Chowdhary, R.K.; Shariff, I.; Dolphin, D. 2003: Drug release characteristics of lipid based benzoporphyrin derivative. Journal of Pharmacy and Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences Societe Canadienne des Sciences Pharmaceutiques 6(1): 13-19

Shao, Z.J.; Moralesi, L.; Diaz, S.; Muhammadi, N.A. 2002: Drug release from Kollicoat SR 30D-coated nonpareil beads: evaluation of coating level, plasticizer type, and curing condition. Aaps Pharmscitech 3(2): E15

Kim, H.W.; Chung, C.W.; Hwang, S.J.; Rhee, Y.H. 2005: Drug release from and hydrolytic degradation of a poly(ethylene glycol) grafted poly(3-hydroxyoctanoate). International Journal of Biological Macromolecules 36(1-2): 84-89

Kalachandra, S.; Lin, D.M.; Stejskal, E.O.; Prakki, A.; Offenbacher, S. 2005: Drug release from cast films of ethylene vinyl acetate (EVA) copolymer: Stability of drugs by 1H NMR and solid state 13C CP/MAS NMR. Journal of Materials Science. Materials in Medicine 16(7): 597-605

Jung, S-Woong.; Jeong, Y-Il.; Kim, Y-Hoon.; Choi, K-Choon.; Kim, S-Ho. 2005: Drug release from core-shell type nanoparticles of poly(DL-lactide-co-glycolide)-grafted dextran. Journal of Microencapsulation 22(8): 901-911

Tachi, Y.; Okazaki, A.; Tanabe, K.; Hatta, H.; Nishimoto, S.-i. 2004: Drug release from functionalized oligodeoxynucleotide by photo-induced electron transfer. Nucleic Acids Symposium Series 48: 79-80

Shi, J.; Alves, N.ál.M.; Mano, J.ão.F. 2006: Drug release of pH/temperature-responsive calcium alginate/poly(N-isopropylacrylamide) semi-IPN beads. Macromolecular Bioscience 6(5): 358-363

Murata, Y.; Miyashita, M.; Kofuji, K.; Miyamoto, E.; Kawashima, S. 2004: Drug release properties of a gel bead prepared with pectin and hydrolysate. Journal of Controlled Release: Official Journal of the Controlled Release Society 95(1): 61-66

Pisal, S.; Zainnuddin, R.; Nalawade, P.; Mahadik, K.; Kadam, S. 2004: Drug release properties of polyethylene-glycol-treated ciprofloxacin-Indion 234 complexes. Aaps Pharmscitech 5(4): E64

Ban Hayashi, E. 2003: Drug releasing stents. Archivos de Cardiologia de Mexico 73(Suppl 1): S17-S20

Mattick, R.P.; Darke, S. 1995: Drug replacement treatments: is amphetamine substitution a horse of a different colour?. Drug and Alcohol Review 14(4): 389-394

Shusko, A.P.; Harding, R.C. 2004: Drug reps: open your arms or bar the door?. Mgma Connexion 4(9): 17

Carley, D.W. 2005: Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part i. Idrugs: the Investigational Drugs Journal 8(4): 306-309

Carley, D.W. 2005: Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part Ii. Idrugs: the Investigational Drugs Journal 8(4): 310-313

Meadows, M. 2003: Drug research and children. Fda Consumer 37(1): 12-17

Hallager, K. 2005: Drug research and the unconscious patient. Ugeskrift for Laeger 167(42): 4015

Bolaños, R.; López Casanello, A.án. 2006: Drug research methodology: fundamentals. Vertex 17(67): 191-196

Stewart, R.H. 1962: Drug research on human subjects. the role of the clinical pharmacologist vs that of the clinical investigator. Northwest Medicine 61: 1036-1037

Miletzki, B.; Gleiter, C.H. 2005: Drug research. first into human in phase i. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48(4): 438-444

Couzin, J. 2004: Drug research. Legislators propose a registry to track clinical trials from start to finish. Science 305(5691): 1695

Sinha, G. 2005: Drug research. Trying to catch troublemakers with a metabolic profile. Science 310(5750): 965-966

Enserink, M. 2006: Drug research. WHO panel weighs radical ideas. Science 314(5804): 1373

Gavăt, V.; Laba, C.D. 2003: Drug residues in food of animal origin. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 107(4): 737-742

Cecchini, M.; LoPresti, V. 2007: Drug residues store in the body following cessation of use: impacts on neuroendocrine balance and behavior--use of the Hubbard sauna regimen to remove toxins and restore health. Medical Hypotheses 68(4): 868-879

Gallant, J.E. 2007: Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 44(3): 453-455

Laurence, J. 2003: Drug resistance among HIV and its "friends". Aids Reader 13(3): 103; 107

Esteban, J.; Granizo, J.-J.; Alvarez-Castillo, M.-C.; Soriano, F. 2004: Drug resistance among Mycobacterium tuberculosis strains in immigrants: is there a real threat everywhere?. Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 10(4): 335-336

Quy, H.T.W.; Lan, N.T.N.; Borgdorff, M.W.; Grosset, J.; Linh, P.D.; Tung, L.B.; van Soolingen, D.; Raviglione, M.; Cô, N.V.; Broekmans, J. 2003: Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 7(7): 631-636

Ansaldi, F.; Valle, L.; Amicizia, D.; Banfi, F.; Pastorino, B.; Sticchi, L.; Icardi, G.; Gasparini, R.; Crovari, P. 2006: Drug resistance among influenza A viruses isolated in Italy from 2000 to 2005: are the emergence of Adamantane-resistant viruses cause of concern?. Journal of Preventive Medicine and Hygiene 47(1): 1-3

Quy, H.T.; Buu, T.N.; Cobelens, F.G.J.; Lan, N.T.N.; Lambregts, C.S.B.; Borgdorff, M.W. 2006: Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 10(2): 160-166

Reid, G.; Seidenfeld, A. 1997: Drug resistance amongst uropathogens isolated from women in a suburban population: laboratory findings over 7 years. Canadian Journal of Urology 4(4): 432-437

Du, S.-g.; Lin, Y.; Wang, X.-d.; Wu, L. 2006: Drug resistance analysis of staphylococcus infection in our hospital from 2003 to 2005. Zhonghua Zheng Xing Wai Ke Za Zhi 22(3): 207-209

Niu, B.-z.; Chen, G.; Li, L.-j.; Wu, Y.-d.; Zhao, Y.-P. 2005: Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 27(5): 606-610

Tolomeo, M.; Simoni, D. 2002: Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Current Medicinal Chemistry. Anti-Cancer Agents 2(3): 387-401

Sakai, T. 2006: Drug resistance and cell survival mechanisms for anticancer drugs. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 127(5): 342-347

Coles, G.C. 2006: Drug resistance and drug tolerance in parasites. Trends in Parasitology 22(8): 348; Author Reply 349

Bottger, E.C.; Pletschette, M.; Andersson, D. 2005: Drug resistance and fitness in Mycobacterium tuberculosis infection. Journal of Infectious Diseases 191(5): 823

Pollock, M.R. 1960: Drug resistance and mechanisms for its development. British Medical Bulletin 16: 16-22

Wang, Y.M.; Dyer, W.B.; Workman, C.; Wang, B.; Peng, N.K.; Lachireddy, K.; Chew, C.B.; Sullivan, J.; Saksena, N.K. 2007: Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Current HIV Research 5(2): 235-250

Anonymous 2005: Drug resistance found in SE area, representing poor, rural population. Resistance screening is indicated. AIDS alert 20(12): 140-141

Sabin, C.A.; Wilkins, E.; Murphy, M.; Fisher, M.; de Ruiter, A.; Easterbrook, P.J.; Leen, C.; Vlahakis, E.; Cane, P.A.; Li, X.; Pillay, D. 2003: Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients. Antiviral Therapy 8(4): 301-308

Sviridov, N.K.; Napolov, I.K. 2003: Prospects of the use of non-ionic X-ray contrast substances during endoscopic retrograde cholangiopancreatography. Vestnik Rentgenologii i Radiologii 18(6): 62-63

Fantinatti-Garboggini, F.; Almeida, R.d.; Portillo, V.íc.d.A.; Barbosa, T.ér.A.P.; Trevilato, P.B.; Neto, C.íc.E.R.; Coêlho, R.ân.D.; Silva, D.W.; Bartoleti, L.A.; Hanna, E.S.; Brocchi, M.; Manfio, G.P. 2004: Drug resistance in Chromobacterium violaceum. Genetics and Molecular Research: Gmr 3(1): 134-147

Upcroft, P. 1998: Drug resistance in Giardia: clinical versus laboratory isolates. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer ChemoTherapy 1(3): 166-168

Menon, N.K. 1963: Drug resistance in Hyderabad. Tubercle 44: 34-38

Papadopoulou, B.; Kündig, C.; Singh, A.; Ouellette, M. 1998: Drug resistance in Leishmania: similarities and differences to other organisms. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer ChemoTherapy 1(4): 266-278

Kisa, O.; Albay, A.; Baylan, O.; Balkan, A.; Doganci, L. 2003: Drug resistance in Mycobacterium tuberculosis: a retrospective study from a 2000-bed teaching hospital in Ankara, Turkey. International Journal of Antimicrobial Agents 22(4): 456-457

Walker, D.J.; Meshnick, S.R. 1998: Drug resistance in Pneumocystis carinii: an emerging problem. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer ChemoTherapy 1(3): 201-204

Oette, M.; Häussinger, D. 2003: Drug resistance in antiretroviral therapy of HIV infection. Medizinische Klinik 98(12): 692-699

Wilson, W.H. 2006: Drug resistance in diffuse large B-cell lymphoma. Seminars in Hematology 43(4): 230-239

Abou-Khalil, B.W. 2004: Drug resistance in epilepsy: is the role of underlying pathology related to multidrug resistance protein?. Epilepsy Currents 4(3): 122-123

Sisodiya, S. 2003: Drug resistance in epilepsy: not futile, but complex?. Lancet. Neurology 2(6): 331

Röckmann, H.; Schadendorf, D. 2003: Drug resistance in human melanoma: mechanisms and therapeutic opportunities. Onkologie 26(6): 581-587

Babiker, H.A.; Mackinnon, M.J. 2005: Drug resistance in malaria: its population biology and implications for control. Acta Tropica 94(3): 161-162

La Porta, C.A.M. 2007: Drug resistance in melanoma: new perspectives. Current Medicinal Chemistry 14(4): 387-391

Kantor, R.; Katzenstein, D. 2004: Drug resistance in non-subtype B HIV-1. Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 29(3): 152-159

Simpson, J.M. 1959: Drug resistance in out-patients treated with sodium PAS and isoniazid cachets. Tubercle 40: 453-456

Richardson, A.; Kaye, S.B. 2005: Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer ChemoTherapy 8(5): 311-321

Kameda, K. 1962: Drug resistance in patients with pulmonary tuberculosis converted to positive during the course of original treatment and its clinical course. Kekkaku: 37: 664-671

Lewis, D.O. 1958: Drug resistance in pulmonary tuberculosis treated with calcium B-PAS. Tubercle 39(4): 247-250

Ito, K.; Wada, M.; Yoshiyama, T.; Ohmori, M.; Ogata, H. 2004: Drug resistance in recurrent cases of tuberculosis. Kekkaku: 79(8): 461-467

Wollheim, F.A. 2003: Drug resistance in rheumatology: an area in search of investigators. Current Rheumatology Reports 5(5): 333-335

Zhang, D-zhi. 2007: Drug resistance in the patients with chronic hepatitis B: prevention and treatment. Zhonghua Gan Zang Bing Za Zhi 15(1): 57-58

Williamson, J.; Rollo, I.M. 1959: Drug resistance in trapanososmes: cross-resitance analyses. British Journal of Pharmacology and ChemoTherapy 14: 423-430

Williamson, J. 1959: Drug resistance in trypanosomes: effects of metabolic inhibitiors, pH and oxidation-reduction potential on normal and resistant Trypanosoma rhodesiense. British Journal of Pharmacology and ChemoTherapy 14: 443-455

Vollum, R.L. 1955: Drug resistance in tubercle bacilli. Tubercle 36(3): 66-68

Negi, S.S.; Gupta, S.; Lal, S. 2003: Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002). Journal of Communicable Diseases 35(2): 74-81

Rodrigues, P.; Gomes, M.G.M.; Rebelo, C. 2007: Drug resistance in tuberculosis--a reinfection model. Theoretical Population Biology 71(2): 196-212

Marks, J. 1961: Drug resistance in untreated pulmonary tuberculosis in England and Wales during 1960. a survey by the Public Health Laboratory Service. Tubercle 42: 308-313

Raleigh, J.W. 1961: Drug resistance is increasing. Maryland State Medical Journal 10: 479-480

Eysker, M.; Borgsteede, F.H.M.; Ploeger, H.W.; Vellema, P. 2005: Drug resistance makes new control measures of stomach parasites in small ruminants necessary. Tijdschrift Voor Diergeneeskunde 130(7): 205-209

Verrills, N.M.; Kavallaris, M. 2003: Drug resistance mechanisms in cancer cells: a proteomics perspective. Current Opinion in Molecular Therapeutics 5(3): 258-265

Yoshikawa, M.; Ito, A.; Ishikawa, T.; Ikegami, Y. 2004: Drug resistance mediated by ABC transporters. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(1): 1-6

Van Deun, A.; Salim, A.H.; Daru, P.; Das, A.P.K.; Aung, K.J.M.; Hossain, M.A.; Rigouts, L.; Fissette, K.; Portaels, F. 2004: Drug resistance monitoring: combined rates may be the best indicator of programme performance. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 8(1): 23-30

Yerly, S.; Fagard, C.; Günthard, H.F.; Hirschel, B.; Perrin, L. 2003: Drug resistance mutations during structured treatment interruptions. Antiviral Therapy 8(5): 411-415

D'Aquila, R.T.; Schapiro, J.M.; Brun-Vézinet, F.ço.; Clotet, B.; Conway, B.; Demeter, L.M.; Grant, R.M.; Johnson, V.A.; Kuritzkes, D.R.; Loveday, C.; Shafer, R.W.; Richman, D.D. 2003: Drug resistance mutations in HIV-1. Topics in HIV Medicine: a Publication of the International Aids Society Usa 11(3): 92-96

Zou, W.; Wu, N.-p.; Bader, A.; Brockmeyer, N. 2003: Drug resistance of HIV-infected patients after the failure of highly active antiretroviral treatment. Zhejiang da Xue Xue Bao. Yi Xue Ban 32(2): 104-106

Khudushina, T.A.; Voloshina, E.P.; Adamovich, N.V.; Maslakova, M.G.; Terekhova, N.D. 2005: Drug resistance of Mycobacteria tuberculosis in patients with new-onset pulmonary tuberculosis. Problemy Tuberkuleza i Boleznei Legkikh 12: 37-39

Stepanian, E.S.; Sergeev, V.V. 1962: Drug resistance of Mycobacterium tuberculosis during the cycloserine treatment of pulmonary tuberculosis patients. Problemy Tuberkuleza 40(8): 84-87

Senol, G.; Komurcuoglu, B.; Komurcuoglu, A. 2005: Drug resistance of Mycobacterium tuberculosis in Western Turkey: a retrospective study from 1100-bed teaching hospital. Journal of Infection 50(4): 306-311

Vishnevskiĭ, B.I.; Vishnevskaia, E.B. 2003: Drug resistance of Mycobacterium tuberculosis in the North-West of Russia. Problemy Tuberkuleza i Boleznei Legkikh 5: 42-45

Esquivel Medina, E.; Vicite, B. 1962: Drug resistance of Mycobacterium tuberculosis in the ambulatory treatment of tuberculosis. Investigation of 150 cases from the pilot plan for control of tuberculosis in Acapulco, Gro. Salud Publica de Mexico 4: 95-101

Samoĭlova, A.G.; Mar'iandyshev, A.O. 2005: Drug resistance of Mycobacterium tuberculosis is the topical problem of phthisiology. Problemy Tuberkuleza i Boleznei Legkikh 7: 3-9

Tungusova, O.S.; Mar'iandyshev, A.O.; Bewne, H.; Sandwen, P. 2004: Drug resistance of Mycobacterium tuberculosis of the genotype Beijing in imprisonment places in the Arkhangelsk Region. Problemy Tuberkuleza i Boleznei Legkikh 8: 35-41

Liu, D.-Q. 2005: Drug resistance of Plasmodium and rational application of antimalarials. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 23(5 Suppl): 355-361

Ergönül, O.; Imre, A.; Celikbaş, A.; Dokuzoğuz, B.şa. 2004: Drug resistance of Shigella species: changes over 20 years in Turkey. International Journal of Antimicrobial Agents 23(5): 527-528

Kameda, M. 1962: Drug resistance of enteric bacteria. on the transduction of transmissible drug resistance (R) factor with epsilon phage. Nihon Saikingaku Zasshi. Japanese Journal of Bacteriology 17: 873-885

Hashimoto, H. 1962: Drug resistance of enteric bacteria. Superinfection of a host bacterium with 2 R factor. Nihon Saikingaku Zasshi. Japanese Journal of Bacteriology 17: 942-951

Li, R.-Z.; Luo, X.-P.; Ma, X.-Y. 2006: Drug resistance of extended-spectrum beta-lactamase-producing bacteria in children with infectious diseases. Zhongguo Dang Dai Er Ke Za Zhi 8(3): 245-246

Zhou, J.-D.; Guo, J.-J.; Zhang, Q.; Chen, Y.; Zhu, S.-H.; Peng, H.-Y. 2006: Drug resistance of infectious pathogens after liver transplantation. Hepatobiliary and Pancreatic Diseases International: Hbpd Int 5(2): 190-194

Akhundova, K.A. 1962: Drug resistance of pathogenic Escherichia coli to antibiotics and norsulfazol. Antibiotiki 7: 1033-1035

Singh, J.; Ramakrishnan, S.P.; Krishnaswami, A.K.; Prakash, S.; Mammen, M.L.; Ray, A.P. 1952: Drug resistance of pre-erythrocytic forms of Plasmodium gallinaceum Brumpt, 1935. Indian Journal of Malariology 6(4): 457-464

Ushiba, D.; Abe, I.; Endo, T.; Kusama, H. 1955: Drug resistance of tubercle bacilli in experimental animals treated with streptomycin and isoniazid. Kekkaku: 30(3): 114-118 English Summary: 154-155

Seri, I. 1960: Drug resistance of tubercle bacilli in patients with Koch-negative sputum. Tuberkulozis 13: 337-340

Kordy, F.N.S.; Al-Thawadi, S.; Alrajhi, A.A. 2004: Drug resistance patterns of Mycobacterium tuberculosis in Riyadh, Saudi Arabia. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 8(8): 1007-1011

Timperi, R.; Han, L.L.; Sloutsky, A.; Becerra, M.C.; Nardell, E.A.; Salazar, J.J.; Smith-Fawzi, M.C. 2005: Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 9(2): 175-180

Wang, X.-F.; Wang, C.; Qin, Y.-W.; Yan, S.-K.; Gao, Y.-R. 2006: Drug resistance reversal of HL-60/ADR cells by simultaneous suppression of XIAP and MRP. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14(6): 1110-1115

Baird, R.D.; Kaye, S.B. 2003: Drug resistance reversal--are we getting closer?. European Journal of Cancer 39(17): 2450-2461